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ABSTRACT 
 
 Protein palmitoylation refers to the process of adding a 16-carbon saturated fatty acid to 
the cysteine of a substrate protein, and this can in turn affect the substrate’s localization, stability, 
folding, and several other processes. This process is catalyzed by a family of 23 mammalian 
protein acyltransferases (PATs), a family of transmembrane enzymes that modify an estimated 
10% of the proteome. At this point in time, no structure of a protein in this family has been solved, 
and therefore there is poor understanding about the regulation of the enzymes and their 
substrates. Most proteins, including palmitoylation enzymes and substrates, have some level of 
intrinsic disorder, and this flexibility can be important for signaling processes such as protein-
protein interactions and post-translational modifications. Therefore, we assumed that examining 
intrinsic disorder in palmitoylation enzymes and substrates would yield insight into their regulatory 
mechanisms. First, we found that among other factors, utilizing intrinsic disorder predictions led 
to a palmitoylation predictor that significantly outperformed existing predictors. Next, we 
discovered a conserved region of predicted disorder-to-order transition in the disordered C-termini 
of the PAT family. In Erf2, the yeast Ras PAT, we developed a model where this region reversibly 
interacts with membranes, and we found that this region mediates interaction with Acc1, an 
enzyme involved in fatty acid metabolism processes. Finally, we found that an XLID-associated 
nonsense mutation in zDHHC9, the mammalian Ras PAT, removed a disordered region that was 
critical for enzyme localization. Future studies of palmitoylation utilizing the framework of intrinsic 
disorder may lead to additional insights about this important regulatory process. 
 
1 
 
 
 
 
CHAPTER 1 
Protein Palmitoylation 
 
1.1 Functions and Relevance of Palmitoylation 
1.1.1 Introduction to Protein Lipidation 
Protein lipidation refers to the post-translational, covalent attachment of a lipid molecule 
to a protein. Several types of lipidation occur in eukaryotes, which differ in terms of the lipid 
structure, linkage, modified residue, and enzyme (Table 1.1) (1). Different classes of lipidation 
generally serve to increase overall protein hydrophobicity and therefore membrane affinity; 
however, lipidation can affect other aspects of protein structure and function including folding, 
stability, and trafficking. In addition, the different forms of lipid modification differ in their regulation, 
functional consequences, and membrane-binding abilities. Modifications can also differ in their 
subcellular context. For example, cholesterol modifications and GPI-anchors can occur in the 
lumen or extracellular matrix, while others such as prenylation and acylation occur in the cytosol. 
The remainder of this chapter will discuss lipid modifications that occur in the cytosol.  
Prenylation is a class of lipid modification that links an isoprenoid group to a cysteine via 
a thioether linkage (2). The likelihood of protein prenyl modifications can be easily recognized by 
specific features of primary sequence at the modification site, which consist of highly conserved 
C-terminal CaaX (a: aliphatic, X: variable), CC, and CXC motifs. The isoprenyl group can either 
be a farnesyl (C15) or geranylgeranyl (C20) group, which is determined by the identity of the X 
residue in the CaaX motif. Farnesylation is carried out by a single farnesyltransferase (FTase) 
and geranylgeranylation by two enzymes (GGTase I and II), which share a common subunit with 
the FTase (3,4). In the case of C-terminal CaaX motifs, prenylation can be followed by proteolytic 
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cleavage of the -aaX residues, then carboxymethylation of the newly exposed cysteine residue 
carboxyl group. 
 
 
 Acylation refers to the addition of a saturated fatty acid to a protein. N-myristoylation (C14) 
of N-terminal glycines mostly occurs co-translationally, following cleavage of an initiator 
methionine. The newly exposed glycine α-amino group is modified by a myristoyl group via a 
covalent amide linkage. Alternatively, myristoylation can occur post-translationally through 
caspase cleavage of a protein, exposing the α-amino group of a glycine. There are two highly 
conserved N-myristoyl transferases, NMT1 and NMT2, with well-characterized enzymatic 
mechanisms based on high resolution crystal structures, as well as clearly defined preference for 
the α-amino group of an N-terminal glycine (5,6). 
Lipid Structure Linkage 
Reversible or 
Irreversible 
Modified 
Residue 
Enzyme 
Myristate 
 
Amide Irreversible H2N-Gly NMT 
Palmitate 
 
Thioester Reversible Cys 
zDHHC 
PATs 
Palmitate 
 
Amide Irreversible H2N-Cys Hhat 
Palmitoleic 
 
Oxyester Irreversible Ser Porcn 
Farnesyl 
 
Thioether Irreversible Cys Ftase 
GeranylGeranyl 
 
Thioether Irreversible Cys GGTaseI 
GeranylGeranyl 
 
Thioether Irreversible Cys 
GGTaseII/ 
REP 
Table 1.1. Lipid modifications of proteins. Adapted with permission from (1). 
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 Palmitoylation (C16) refers to the addition of palmitate and can occur in the ER lumen or 
the cytosol (7,8). Luminal N-palmitoylation of N-terminal cysteine residues starts with an 
intermediate thioester linkage, followed by a spontaneous rearrangement to a stable amide 
linkage of the exposed α-amino group. Secreted proteins, such as the morphogens Sonic 
Hedgehog and Wnt, are N-palmitoylated and O-acylated respectively. Both of these modifications 
are performed by MBOATs (membrane bound O-acyl transferases) of which there are 11 known 
members, such as Hhat and Porcupine (9,10).  
 Cytosolic S-palmitoylation is the addition of palmitate to a cysteine residue via a thioester 
linkage, and unless otherwise indicated, will be referred to as palmitoylation for the rest of this 
dissertation. This reaction is catalyzed by zDHHC protein acyl transferases (PATs), of which there 
are 23 expressed in mammals (11). This family of enzymes will be discussed in detail later in this 
chapter.  
 Palmitoylation also appears to be enzymatically reversible through a less-understood 
family of protein thioesterases. Only APT1/APT2 and ABHD17 isoforms have been shown to 
depalmitoylate proteins in the cytosol, but it is currently unclear if these represent the entire 
repertoire of depalmitoylation enzymes. Furthermore, while these proteins exhibit some level of 
selectivity, this appears to be dependent on cellular context: for example, it appears that ABHD17 
is specific for Ras proteins in HEK293T cells, but not in neurons (12,13). Therefore, major areas 
of interest are determining additional candidates and the basis of selectivity.  
 Nevertheless, the reversibility of palmitoylation makes it unique from other lipidations (Fig. 
1.1), and therefore has interesting regulatory implications comparable to those of other 
enzymatically reversible modifications such as acetylation and phosphorylation.   
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 These lipid modifications often occur in tandem; for example, palmitoylation is often 
preceded by myristoylation or prenylation (14,15).  One reason for this seems to be related to 
differences in membrane affinities between different lipid modifications. Using fluorescently-
labeled lipopeptides, Silvius and coworkers were able to estimate membrane-binding affinities by 
titrating vesicles containing a quencher (DABS-PC). Subsequent addition of quencher-free 
vesicles caused an increase in fluorescence, and quantifying this rate represented the reversibility  
of this reaction. While palmitate and geranylgeranyl exhibited stable membrane binding affinity, 
myristoylglycine and farnesylcysteine had much higher dissociation constants and thus higher 
fractions of lipopeptide membrane-binding turnover. Therefore, the supposition made from these 
studies was that myristoyl and farnesyl modifications, while sufficient for membrane binding 
(contributing 8-12 kcal mol-1), are highly reversible and require an additional signal for stable 
membrane binding (16,17). This additional signal (contributing 3-4 kcal mol-1) comes in the form 
of either electrostatic interactions (surrounding basic residues) or additional hydrophobicity 
(nearby palmitoylated residue or residues) (18). This situation becomes even more complex when 
one considers that lipidated proteins have various specificities for different cellular membranes. 
This can be explained by a number of factors, including protein-protein interactions, affinity 
Figure 1.1: Reversible protein palmitoylation by PATs and thioesterases. 
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towards certain phospholipid compositions, vesicle-mediated trafficking, and subcellular 
localization of palmitoylation enzymes.  
1.1.2 Functional Consequences of Palmitoylation 
 As previously discussed, palmitate modifications are mainly known to modify protein 
function by serving as a membrane ‘anchor’ for proteins, where one palmitate modification is 
independently sufficient for stable membrane binding. However, palmitoylation can also affect 
other aspects of protein function, either related or unrelated to trafficking. In terms of trafficking-
related functions, it can affect the membrane specificity of a protein, likely through the localization 
of its cognate palmitoylation enzyme, effectively serving as a kinetic trap (18,19). Within a 
membrane, palmitoylated proteins appear to have affinity towards lipid rafts (20), which are 
composed of sphingolipids and phospholipids containing saturated fatty acids that self-associate 
to form a ‘liquid-ordered’ phase. The saturated nature of palmitate groups would promote 
association with this tightly-packed membrane microdomain. 
 Protein palmitoylation also affects a number of protein functions independent of 
membrane trafficking. It has been observed to promote protein stability, through preventing 
aggregation in the case of huntingtin protein (21), or recognition of Tlg1 by ubiquitin ligases (22). 
The gating kinetics of some ion channels have also been observed to be altered by palmitoylation, 
including Kv 1.1 and Na 1.5 (23-28). Recently, palmitoylation has been suggested to affect protein 
folding by serving as a hydrophobic core, presumably through co-translational modification and 
subsequent folding of the nascent protein (29). While studies are limited due to technical 
limitations of producing purified palmitoylated protein, a recent study of the TEA domain (TEAD) 
family of transcription factors demonstrated that the palmitoylated cysteine was at the 
hydrophobic core of the protein, and the modification affected proper folding and stability (29). 
Finally, palmitoylation has been observed to affect the phosphorylation propensity of surrounding 
residues, as in the cases of endothelial nitric oxide synthase, growth-associated protein 43, β2-
adenergic receptor, dopamine transporter, and the BK channel (30-35). Overall, it is clear that the 
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change in protein physicochemical composition upon palmitoylation can have significant effects 
on its function, even outside of the context of membrane trafficking functions.  
1.1.3 Efforts to Understand the Prevalence of Palmitoylation 
 In the past ten years, several new proteomic methods to detect palmitoylated proteins 
have been deployed, primarily acyl-biotin exchange (ABE) based methods and ‘Click’-based 
methods (36). ABE is a more indirect method based on replacement palmitates on palmitoylated 
cysteines with a group that enables separation, such as biotin or polyethylene glycol (12,37-40). 
More direct labeling methods such as ‘click’ chemistry involves incorporation of palmitate analogs 
such as either ω–alkynyl-palmitate or an azido-palmitate in cells, and these analogs can be 
subsequently labelled with tagged azides or triarylphosphines, respectively (41-45). Several 
thousand new palmitoylated substrates have been experimentally identified by deploying these 
methods on specific organisms, subcellular compartments, cell types, and other classifications. 
Recent efforts utilizing this wealth of data have estimated that ~10% of eukaryotic proteomes are 
palmitoylated (46,47). This subset is enriched in proteins promoting metabolism, localization, 
trafficking, and intracellular/extracellular signaling, suggesting this modification may have 
significant relevance in cell homeostasis. 
1.2 Palmitoylation Enzymes 
1.2.1 Discovery, Diversity, and Importance of zDHHC PATs 
 Instances of palmitoylation can be observed in the literature as early as 1979 (48). 
However, there was considerable debate as to how this reaction proceeds in the cell. As other 
reactive thiol modifications such as nitrosylation and oxidation proceed without enzymes, a 
popular hypothesis was that palmitoylation occurred in a non-enzymatic fashion; in fact, peptides 
derived from palmitoylated proteins were readily modified in the presence of palmitoyl-CoA (49-
51). While partial purifications from rat liver microsomes had palmitoyltransferase activity, 
subsequent studies revealed that thiolase A was responsible for this observation (52). As thiolase 
7 
 
A is a peroxisomal enzyme, it was considered unlikely to be a physiologically relevant 
palmitoyltransferase. 
 Studies in yeast revealed the identity of the PAT enzymes and settled, for the most part, 
the debate whether this palmitoylation is enzymatic or non-enzymatic. The yeast Ras PAT 
complex Erf2-Erf4 was identified using a genetic screen looking for genes that affect 
palmitoylation-dependent Ras2 function (53), and subsequent biochemical analyses 
demonstrated that Erf2-Erf4 was a bonafide palmitoyltransferase for Ras2 (54). Similar concurrent 
studies identified Akr1 as the Yck2 palmitoyltransferase (55,56). While partially conserved, Erf2 
and Akr1 had several key differences, including the presence/absence of a regulatory subunit and 
conservation of residues in the cysteine-rich domain. Subsequent bioinformatics analyses 
revealed that PATs are present in all eukaryotes, with 7 in yeast and 23 in mammals.  
  Discovery of this new enzyme family, while important, still did not preclude the possibility 
that the majority of physiological palmitoylation in the cell is not enzyme-catalyzed. Using a 
combination of yeast genetics and innovative proteomic methods, Roth and coworkers addressed 
this question. Briefly, by deletion of 6/7 of the PAT genes in yeast, most detectable palmitoylation 
in the cell was eliminated, suggesting that PAT enzymes are responsible for the majority of 
palmitoylation in the cell (38). Additionally, the observation that at least one PAT was required for 
cell survival implied that palmitoylation is generally important for cell homeostasis. 
1.2.2 Substrate Specificity of Protein Palmitoylation 
While our knowledge of palmitoylated substrates is expanding, the mechanism of PAT 
recognition of substrates in the context of the cell is a point of debate in the field. It has been 
proposed that the majority of palmitoylation events occur at cytosolic face of the Golgi apparatus, 
allowing for binding of palmitoylated proteins to the Golgi membrame and subsequent entrance 
of palmitoylated proteins into the secretory pathway, targeting to the plasma membrane, and 
eventually redistribution to all cellular membranes (19). This proposed process is non-specific in 
that the stereochemistry of the palmitoylated cysteine and the surrounding local sequence 
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composition do not affect the thermodynamics of membrane association. In other words, there 
may be redundancy of function between the 23 zDHHC PATs. Indeed, knockdown of zDHHC9 in 
heterologous cells does not significantly affect H-Ras localization (19), although they are one of 
the few validated enzyme-substrate pairs using purified proteins (57).  
The issue of zDHHC PAT specificity has not been resolved, and questions remain as to 
why nature would conserve 23 zDHHC genes with seemingly redundant functions. Differential 
tissue expression of the 23 zDHHC PATs is one simple explanation (58). Also, not all zDHHC 
genes necessarily encode functional enzymes, as a few PATs do not display steady state acyl-
enzyme intermediates (59) and may be vestigial or have functions unrelated to catalytic activity, 
such as the catalytically-independent actin regulation functions of yeast Swf1 (60). The idea of 
overlapping substrate specificity may also explain the seemingly large number of zDHHC genes.  
The majority of enzyme-substrate pairs have been identified by overexpression of a 
substrate of interest with each of the 23 zDHHC PATs, and subsequent quantification of increase 
in palmitoylation (61). While informative, these types of studies do not reflect physiological 
conditions, and should therefore be interpreted with caution and followed up with additional 
experiments. Examples of enzyme-substrate pairs identified through these types of studies 
include the palmitoylation of SNAP receptor protein SNAP25 by zDHHCs 3, 7 and 17 (62); the 
transmembrane ER chaperone, calnexin, which is exclusively palmitoylated by zDHHC6 (63); and 
integrin, α6β4, is palmitoylated by DHHC8 (64). Several reviews and databases have compiled 
comprehensive lists of these enzyme-substrate pairs (46). In these studies, more than one 
enzyme is often shown to palmitoylate a single substrate, and in these cases zDHHC3 and 
zDHHC7 have the highest frequency of appearance. These enzymes have been proposed to be 
relatively non-specific enzymes, while other subsets of PATs are more specific towards different 
types of substrates. The reverse paradigm seems to hold true as well; that is, one enzyme 
generally has more than one associated substrate, even in enzymes with seemingly higher 
specificities.  
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A notable exception to this broad, overlapping substrate specificity is zDHHC9, which to 
our knowledge has only one associated substrate based on overexpression studies  in 
heterologous cells; the alternatively spliced STREX variant of big potassium (BK) channels (65). 
While this could mean that zDHHC9 has high specificity for substrates, this could also be a 
reflection of the limitations of traditional enzyme-substrate overexpression studies, which do not 
truly reflect physiological conditions. Another alternative explanation would be that amounts of 
functional zDHHC9 is limited by amounts of its regulatory subunit required for enzyme function, 
GCP16, which is not considered in overexpression studies (57). As many other zDHHC PATs (1, 
2, 4, 5, 6, 11, 14, 15, 16, 18, 19, 22, 24) are underrepresented in these overexpression studies, 
further understanding the role of regulatory subunits in PAT biochemistry may be a new avenue 
of elucidating enzyme-substrate relationships, and will be explored later in this dissertation. 
Regardless, whether the phenomenon of overlapping substrate specificity is simply because of 
PAT subcellular localization, sequence-encoded specificity (or lack thereof), both, or neither is 
still a topic of debate. Here, I will further discuss these two models. 
Localization-mediated substrate specificity. A potential explanation of the phenomenon of 
overlapping substrate specificity is that the complexity of PAT localization may increase in 
specialized cells containing unique compartments. For example, zDHHC2, zDHHC3, and 
zDHHC17 all localize to the Golgi in HEK-293T cells (58); however, in the neuron, only zDHHC3 
localizes to the Golgi, while zDHHC2 localizes to postsynaptic vesicles and zDHHC17 localizes 
to the axon in fly neurons (66,67). In this model, substrate specificity is conferred by the location 
of the PAT – Golgi-localized zDHHC3 serves as a ‘constitutive’ enzyme, palmitoylating newly-
translated proteins which target to the plasma membrane and subsequently travel to different 
neuronal cell compartments through heretofore undescribed mechanisms. When the substrates 
reach their destination, a cycle of palmitoylation and depalmitoylation is maintained by a 
combination of ‘compartment-specific’ PATs (in the case of the neuron, synaptic vesicle-bound 
zDHHC2 and axonal zDHHC17) and thioesterases (68). Another example of unique PAT 
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localization conferring substrate specificity is T. gondii zDHHC7. This enzyme is found in 
rhoptries, unique organelles found only in Apicomplexans, and this localization is required for 
palmitoylation of the Armadillo Repeats-Only (ARO) rhoptry protein (69). These cases of unique 
subcellular localizations, combined with changes in relative tissue expression in zDHHC PATs, 
may be an explanation for the diversity of the zDHHC family.  
Whether this model of zDHHC PATs falling under ‘constitutive’ versus ‘compartment-
specific’ subgroups is a general paradigm in all cell types is an underexplored question in the 
field. Therefore, expanding the knowledge of zDHHC PAT subcellular localization in cell types 
with unique compartments and organelles will further elucidate mechanisms of substrate 
specificity. Even within the subset of Golgi-localized zDHHC PATs, it is currently unknown if 
different zDHHC PATs localize to the same or different Golgi cisternae or subdomains, which may 
confer specificity even in cell types lacking unique compartments. 
Sequence-mediated substrate specificity. While it is generally assumed that there is no 
consensus amino acid sequence to predict a palmitoylation site, several trends have been 
observed that involve the sequence context of a putative cysteine receiver. As discussed 
previously, cysteines proximal to prior lipidations can be efficient substrates for palmitoylation.  
Also, cysteines juxtaposing transmembrane domains or within transmembrane domains are also 
efficiently palmitoylated (38,70). While it would be tempting to postulate that different PATs are 
specific for these unique contexts, there are no clear trends in mammalian cells (59), and it is 
likely that prior membrane association enhances protein palmitoylation. 
There are some instances where substrate specificity is also encoded in the primary 
sequences of a particular enzyme and/or its substrate. A well-characterized example of substrate 
sequence mediating specificity is the scenario is zDHHC17 and SNAP25b, where Pro117 of 
SNAP25b specifically interacts with the zDHHC17 (71). It should be noted that while this specific 
residue facilitates interaction with zDHHC17, it is not necessarily required, as it does not mediate 
interactions between its other associated PATs zDHHC3, zDHHC7, and zDHHC15. Instances of 
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enzyme/substrate interaction mediated by enzyme sequence include the ankyrin repeats of 
zDHHC17 interacting with Huntingtin protein (72), the armadillo repeats of Pfa3 interacting with 
Vac8 (73), and the PDZ-binding motifs of zDHHC5/8 interacting with the PDZ domain of GRIP1b 
(74). It remains to be seen if these highly specific enzyme/substrate interactions mediated by 
sequence are exceptional circumstances, or if this serves as a more general mechanism of 
recognition. 
1.2.3 Structure and Mechanism of zDHHC PATs 
General features- While no crystal structure of a PAT has been determined, a number of features 
have been inferred through sequence and biochemical analyses. Generally, PATs are composed 
of 4-6 transmembrane (TM) regions, a 51 amino acid catalytic cysteine-rich domain (CRD), and 
N/C-termini. Various conserved amino acid motifs have also been identified: the DPG (Asp-Pro-
Gly) motif, which is found after transmembrane region 2, the catalytic DHHC (Asp-His-His-Cys) 
motif, which is found within the CRD, and the TTxE (Thr-Thr-X-Glu) motif, which is found 
immediately after the last transmembrane region (Fig. 1.2) (11). Functional roles of the DPG and 
TTxE motifs have not been elucidated.  
While these features are mostly conserved throughout the family, some unique variations 
still exist: for example, yeast Akr1 (and human homologs zDHHC13, 16, and 17) has several 
ankyrin repeats in their N-termini (75,76). Furthermore, Akr1, Akr2, Pfa5, and zDHHC22 are 
missing some of the characteristic cysteines and histidines of the CRD (11). Still, the DHHC motif 
is conserved throughout the family, and recently, our group has demonstrated that this motif is 
the site of catalysis (77).  
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Catalytic mechanism- The palmitoylation reaction occurs in two steps (Fig. 1.3). In the presence 
of a palmitoyl-CoA donor, the cysteine residue of the DHHC motif rapidly undergoes 
autopalmitoylation to create a thioester-linked palmitoyl-PAT intermediate. In the presence of 
substrate, the palmitoyl moiety is subsequently transferred from the DHHC cysteine to the 
substrate cysteine. In the absence of substrate, the autopalmitoylation intermediate undergoes 
rapid hydrolysis and a cycle of re-palmitoylation/hydrolysis occurs (77,78).  
Figure 1.3: Two-step mechanism of protein palmitoylation.  The PAT undergoes autopalmitoylation in the presence 
of acyl-CoA. Depending on the presence or absence of substrate, there are two possible fates: transfer or hydrolysis, 
respectively. Regardless, the enzyme is recycled to its original state, ready to begin the process again (73, 74).  
 
Figure 1.2. Topology of zDHHC PATs. This family of proteins is characterized by 4-6 transmembrane regions and a 
catalytic DHHC (Asp-His-His-Cys) motif within a cysteine-rich domain (CRD). WebLogo represents conservation of all 
mammalian PATs within the CRD.  
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It should be noted that while this mechanism usually applies to palmitoyl-CoA donors, 
acyl-CoA donors in general can participate in the PAT reaction, and purified DHHC PATs display 
acyl-CoA length specificities (78,79). While the modification is generally assumed to be 
palmitoylation, it is possible and likely that PATs utilize different acyl-CoA chain lengths in the cell 
dependent on specificity and context. 
Functional significance of the C-terminus- The zDHHC PAT C-terminus appears to be important 
for the localization of many mammalian PATs. Greaves et al. found that variable ends of zDHHC2 
and 15 were essential to normal localization (80), which they further supported through 
identification of short, lysine-based sorting signals at the end of the C-terminus of zDHHC4 and 
zDHHC6 essential to endoplasmic reticulum retention (81). Interestingly, truncation of the 
zDHHC3 C-terminus had no effect on localization. This, combined with the observation that only 
the Erf2 N-terminus appears to regulate subcellular localization (see Chapter 4), may indicate that 
there is no universal sequence feature that regulates zDHHC PAT localization.  
While biochemical mechanisms remain underexplored, the C-terminus of some PATs also 
are essential for palmitoylation of substrates. González Montoro et al. identified a semi-conserved 
region (termed the ‘PaCCT’ motif) in the C-terminus as well as a single conserved aromatic 
residue within this motif (82). It was suggested that this motif was important to Swf1 palmitoylation; 
however, the biochemical mechanism was not determined. This motif is not universally applicable, 
as it is not found in zDHHC1, 3, 7, 11, 21, 22, and 23. In biochemical assays of purified proteins, 
our group found that the Erf2 C-terminus (which contains a PaCCT motif) contributes to steady-
state autopalmitoylation and the subsequent transfer of palmitate to Ras2, further suggesting 
biochemical relevance in terms of palmitoyltransferase function (83). Some post-translational 
modifications have also been observed in PAT C-termini, which will be discussed in the next 
section. Regardless, these studies suggest multiple functional roles for the C-terminus, and these 
functions may be partially conserved. 
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1.2.4 Potential Regulatory Mechanisms of zDHHC PATs 
Post-translational modifications- While post-translational modifications are generally known to 
alter the function of proteins, few bona fide regulatory PTMs have been identified in PATs. A 
subset of six lysines in the Erf2 C-terminus are polyubiquitinated, leading to proteasome-mediated 
degradation (83). Nearly every zDHHC protein has been identified in high-throughput interaction 
studies of ubiquitin, suggesting that ubiquitination may be a common regulatory modification (84-
87). Proteomic studies identified palmitoylated cysteines in the C-termini of zDHHC5, zDHHC6, 
and zDHHC8 (88); however, the functional relevance of these have not been explored. It also 
appears that phosphorylation can potentially mediate PAT function. In neurons, zDHHC5 forms a 
complex with PSD-95 and Fyn kinase, promoting phosphorylation of the zDHHC5 endocytic motif 
(YDNL). This serves to prevent binding of the endocytic adaptor protein (AP2) and stabilizes 
zDHHC5 at the synaptic membrane (89). Also in neurons, phosphorylation of zDHHC8 (but not 
other zDHHCs) by PKMζ potentially regulates synaptic PSD-95 accumulation (90).  
Protein-protein interactions- The best-characterized example of a regulatory PPI with a PAT is 
the case of regulatory subunits. Erf2 forms a heterodimeric complex with Erf4, and zDHHC9 (and 
presumably homologs zDHHC14 and zDHHC18) forms a similar complex with GCP16 (57,83,91). 
These subunits are required for PAT function, and in the case of Erf2-Erf4, Erf4 serves to both 
increase Erf2 stability and stabilize the palmitoyl-Erf2 intermediate. This interaction is most likely 
regulated by at least the CRD, as mutations in conserved cysteines within this region reduce 
levels of Erf2-Erf4 interaction (Cheryl Budde, unpublished data). It is still unknown if other 
regulatory subunits that complex with other zDHHC proteins exist, although some interacting 
candidates have been identified, such as the zDHHC6-selenoprotein K (Selk) complex and the 
HIP14-HTT complex (21,92). Both of these interactions appear to contribute to palmitoylation of 
substrates, however biochemical validation using purified proteins is required to determine the 
mechanistic role of these interacting proteins.   
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Divalent cation binding- In the catalytic CRD of Erf2, there is an enrichment of conserved 
cysteines and histidines, several of which are essential to palmitoylation-dependent Ras2 function 
(77). This implied that zDHHC proteins were not only able to coordinate divalent metal cations, 
but that this was essential to the function of the protein. Recent studies have found that zDHHC 
proteins coordinate two zinc ions, and these are essential to the stability of the protein (93,94).  
Oligomerization- Though the mechanisms remain unclear, it appears that some zDHHC proteins 
can self-associate in cultured mammalian cells, including zDHHC2 and zDHHC3 (95). Purified 
zDHHC3 resolved as monomers or dimers on native gels, and covalently-linked dimers appeared 
to have less catalytic activity than the monomeric counterparts, potentially demonstrating 
oligomerization as a mode of catalytic regulation (95). However, it is unclear if oligomerization of 
zDHHC proteins is a physiologically relevant phenomenon.  
1.3 Closing Remarks 
 Palmitoylation is clearly an important regulatory modification in the cell, as it affects a high 
percentage of the proteome and can have various significant effects on a protein’s structure and 
function. Through the discovery of the zDHHC PAT family and advances in palmitoyl proteomic 
techniques, a clearer view of palmitoylation in the cell is beginning to emerge. However, several 
fundamental aspects of palmitoylation need to be elucidated to truly begin to understand the 
relationship between palmitoylation and cell homeostasis. This dissertation will address the topics 
of enzyme-substrate specificity and zDHHC enzyme regulations, using several concepts and tools 
of the field of protein intrinsic disorder. 
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CHAPTER 2 
 
Intrinsically Disordered Proteins and Regions 
 
2.1 History of IDPRs 
2.1.1 The Structure-Function Paradigm 
 Until recently, the predominating view of protein folding was the ‘sequence-structure-
function’ paradigm; essentially, aspects of the primary amino acid sequence of a protein (e.g., 
physicochemical properties of every amino acid, the distribution of amino acids) contain all of the 
information necessary for a protein to fold in its most stable conformation (defined as the free 
energy minimum), and this conformation is what dictates the function of the protein. This view is 
championed by two classical observations: Anfinsen’s dogma and Levinthal’s paradox (96,97).  
Anfinsen’s classical experiment was simple yet elegant: given a protein with a certain 
stable conformation, if this protein is forced to unfold, will it refold into the same original 
conformation, and therefore retain the same function? Anfinsen unfolded ribonuclease A using 
both urea and 2-mercaptoethanol (2-Me or β-Me), protein denaturants that work by preferentially 
interacting with the peptide backbone and reducing disulfide bonds, respectively (98). 
Subsequently, the protein was returned to its original environmental conditions (removing urea 
and 2-Me). The refolded protein had >90% of catalytic activity as the untreated enzyme, 
suggesting that the structural state was essentially the same (96). The idea that arose from this 
and related studies was that when protein folding occurs, the protein must only have one free 
energy minimum, this minimum must be kinetically accessible, and the native state must not be 
affected by small changes in environmental conditions. 
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 Levinthal’s paradox is a thought experiment, to understand the path a nascent protein 
takes to fold in its final conformation. A newly generated protein could stochastically sample all 
possible conformations to find the free energy minimum, or a more complex search process could 
occur. Given a polypeptide chain of 100 residues, there would be 198 phi and psi bond angles, 
each bond having three potential stable positions. Therefore, this protein would have a total of 
~3198 different conformations (97). As proteins are known to fold on the order of milliseconds to 
seconds, the time scales required to sample this enormous number of conformations are simply 
incompatible. Therefore, a nascent protein has a less stochastic search process, and subsequent 
studies have supported two non-mutually exclusive models of protein folding. In the diffusion-
collision model, small regions of each protein (‘microdomains’) form secondary structure, then 
subsequent environment-guided diffusion causes collision of microdomains, eventually forming a 
tightly packed tertiary structure (99). In the nucleation-condensation model, secondary and tertiary 
structure formation happen simultaneously (100,101). 
Several exceptions were found to this generalized rule of primary sequence being the only 
factor required for a protein to correctly fold, and it was suggested that these exceptions revolved 
around susceptibility to aggregation. For example, chaperones are often required for proper 
folding by protecting a protein from the external environment while folding, as the exposed 
hydrophobic residues of an unfolded protein would make it highly prone to aggregation. 
Membrane proteins with hydrophobic transmembrane domains are also a major exception for 
similar reasons, requiring detergents to renature correctly. Nevertheless, sequence generally 
seemed to dictate the folding of a rigid structure, and this structure appeared to be related to its 
protein function.  
Many of the early analyses of structure-function relationships were in enzymes (as with 
Anfinsen’s experiment), primarily because the output of an enzymatic reaction provided a 
convenient, quantitative readout that could be analyzed in the context of structural changes. The 
first model of structure-function relationship was initially proposed by Emil Fischer to explain the 
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exquisite specificity of different hydrolyzing enzymes towards α- or β-glycosidic bonds. In this ‘lock 
and key’ model, a correctly sized substrate (key) perfectly fit an active site (lock) (102). A more 
sophisticated version of this developed as the ‘induced fit’ model, which assumes a small degree 
of flexibility in the active site to conform to a substrate that is a slightly different shape (103). 
Therefore, the general assumption was that a protein’s three-dimensional structure dictated its 
function (structure-function paradigm).  
2.1.2 IDPs – An Exception to the Structure-Function Paradigm 
Natively unfolded proteins were observed sporadically in the literature. However, because 
of the predominant view of a 3-D structure being required for a protein’s function, classical 
biochemical methods of determining a given protein’s function were biased towards enzymes, 
and therefore structured proteins. Unfolded proteins were largely ignored, as they were either not 
amenable to traditional biochemical analyses, regarded to be non-functional, unstable in the cell, 
or even considered to be the result of an unsuccessful purification (104).  
A series of critical observations from the late 1990s to the early 2000s began to reveal the 
importance and prevalence of intrinsically disordered proteins and regions. Development of per-
residue disorder predictors revealed the physicochemical sequence characteristics of disordered 
regions, and application of these predictors demonstrated a much higher than expected 
prevalence in the proteomes of eukaryotes (105-108). An analysis of proteins known to be mostly 
ordered or mostly disordered revealed that disordered proteins occupy a unique region in charge-
hydrophobicity space, representing a simplified, accessible method of predicting protein disorder 
(109). Finally, critical reviews of the literature compiled many of the isolated instances of intrinsic 
disorder participating in protein function, which built an argument for functional relevance and 
evolutionary advantages of protein intrinsic disorder (104,110,111). The physicochemical 
properties and functional advantages of disordered regions will be further discussed later in this 
chapter. Regardless, it was clear that the traditional structure-function paradigm had to be 
substantially modified in order to account for these observations. 
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These seminal observations initiated development of numerous computational and 
experimental tools to analyze intrinsic disorder, leading to an explosion of literature in the field 
and eventually greater acceptance of intrinsic disorder as a prevalent and functionally relevant 
phenomenon. A number of biochemical, biophysical, and computational techniques can be 
utilized to determine the level of intrinsic disorder in a protein of interest. While a detailed 
examination of these techniques is beyond the scope of this dissertation, it is important to note 
that each of these techniques have advantages and disadvantages due to experimental 
limitations combined with the diversity and conformational heterogeneity of IDPRs. Therefore, 
intrinsic disorder is best analyzed through multiple, complimentary techniques.  
This body of literature has addressed some of the key conceptual issues that the 
phenomenon of intrinsic disorder poses, such as the idea that intrinsic disorder can be a native 
state in the cell and that disordered regions can have functions truly independent of structure. 
However, several fundamental issues critical to the progress of the field remain, primarily 
understanding the general characteristics, regulation, and function of IDPs in the cell. In addition 
to development of new, highly-sensitive methods, this will also require elucidating functions of 
intrinsic disorder in previously unexplored protein families.  
2.2 Biophysical Characteristics of Disordered Regions 
 The free energy landscape of an IDP represents a simple way to distinguish it from a 
folded protein. While a folded protein would have one clearly defined minimum representing the 
most stable and lowest energy state, an IDP would have no clearly defined minimum with a 
relatively ‘flatter’ landscape, which allows the IDP to populate a number of different conformational 
states (Fig. 2.1) (112). However, IDPs can have a number of unique conformational behaviors 
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making it distinct from denatured proteins. Here, I will discuss how the physicochemical features 
of an IDP can affect the conformational dynamics of the protein.   
2.2.1 Sequence  
Like folded proteins, the physicochemical factors that result in a protein being ‘intrinsically 
disordered’ are partially encoded in sequence. While different classification schema may have 
slight variations, analyses of known disordered proteins have revealed general rules: more 
hydrophobic, non-polar residues are considered ‘order-promoting’, charged, hydrophilic residues 
are considered ‘disorder-promoting’, and small non-polar residues are considered ‘neutral’ (Fig. 
2.2) (113,114). Cysteine and proline represent two unique cases: cysteine primarily because of 
its involvement in disulfide-bond formation (order-promoting), and proline because of its well-
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Figure 2.1. Relationships between protein folding and energy landscapes. (A) A well-folded protein has a clearly 
defined, kinetically accessible thermodynamic minimum. (B) A disordered state may have a weakly funneled landscape, 
where there is a predominant sub-state in the ensemble but not enough of a minimum for stable structure. (C) A rough, 
nearly level landscape where there are shallow minima with relatively little entropic penalty between each state. Figure  
is reprinted from (112). Copyright 2008 National Academy of Sciences. 
Figure 2.2. Amino acid composition of IDPRs relative to globular proteins. Amino acids are sorted from least to 
most disordered based on peak values from DisProt 3.4. Figure is reprinted with permission from (113). 
A B C 
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understood role as a ‘structure-breaker’ (disorder-promoting). Also, IDPRs often have low 
complexity sequences, although this is not necessarily a requirement of unfoldedness.  
All residues that can gain charge at physiological conditions fall under the category of 
disorder-promoting, with the exception of histidine, likely because of its propensity to bind divalent 
metal ions such as zinc and nickel, combined with the sensitivity of its pKa to physiological pH 
ranges (the majority of histidine is uncharged at neutral pH). The effect of charge (more 
specifically, the net charge) on the foldedness of a protein has been well-described, beginning 
with the observation that IDPs occupy a unique region in charge-hydrophobicity space (Fig. 2.3) 
(109,115). This was proposed to function through charge-charge repulsions preventing essential 
folding events such as microdomain collision.  
Besides net charge, the pattern of positive and negative charges can affect the level of 
compaction of a disordered protein. The pattern of charge can be denoted as κ, a value that lies 
between 0 and 1, where increasing values represent less well distributed charge in a protein. 
Proteins with lower κ have structures resembling self-avoiding random walks, while proteins with 
Figure 2.3. IDPs occupy a unique region in charge-hydrophobicity space. The boundary line is the arbitrary 
separation value determined by Uversky et al., where proteins to the left can be roughly classified as disordered. The 
optimal line determined by Oldfield et al. is <charge> = 2.743<hydropathy> - 1.109. Figure is reprinted with permission 
from (115), 
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higher κ form more collapsed, hairpin-like structures (116). While the number of studies in 
biological systems are limited, tuning of κ clearly appears to have remarkable effects on 
disordered protein function (117-119).  
The overall hydrophobicity of a protein also appears to influence the level of protein 
disorder, evidenced by most hydrophobic/nonpolar residues falling under the category of order-
promoting residues (with the main exception of proline due to its role as a structure-breaker). This 
is the case primarily because of the requirement of hydrophobic collapse for an ordered globular 
protein. The few hydrophobic residues that IDPRs have are often highly conserved, likely because 
of their importance in binding. While IDPs generally have high hydrophilicity, the intrabackbone 
interactions due to poor water solvency may trigger collapsed structures (120,121).  
2.2.2 Structural Dynamics 
As would be suggested in the previous section, a final protein structure is a representative 
of the level of all the physicochemical factors encoded in sequence, as well as other factors such 
as environmental conditions. Therefore, the level of disorder in a protein structure can be 
considered a heterogeneous spectrum (Fig. 2.4) (122). For convenience, disordered proteins are 
often classified by their compaction level (such as collapsed or extended), context (e.g., linkers 
and tails), residual secondary structure, or other characteristics. One widely used classification 
scheme of disordered proteins refer to their resemblance to an intermediate folding state, primarily 
either native molten globule (collapsed but solvent accessible, with mostly formed secondary 
structure), native pre-molten globule (less compact than molten globule, partially formed 
secondary structure), and native coil (self-avoiding random walk) states.  
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Though IDPRs have interesting heterogeneity in isolation, their biologically relevant 
context is often when they interact with macromolecules such as proteins, nucleic acids, lipids, 
etc. Like when in isolation, IDPRs have peculiar behaviors when forming interactions, and 
generally these behaviors fall within two extremes of either disorder-to-order transitions (coupled 
folding and binding) or wholly disordered interactions (fuzzy complexes).  
Coupled folding and binding- The most commonly observed functional form of functional intrinsic 
disorder is when a disordered region folds in the presence of a binding partner, often termed 
MoRF (molecular recognition feature) (123-125). While most observed instances are α-helical, 
formation of β-sheets and irregular (but rigid) structures also occur. These regions are natively 
disordered primarily because while the region itself has high secondary structure propensity, 
surrounding residues have high conformational entropy. The native disorder of these regions 
introduce an entropic penalty in order to fold and bind, which results in an interaction that has 
high specificity while having relatively low affinity, ultimately providing a number of advantages 
over ordered proteins for complex signaling processes.  
Figure 2.4: Heterogeneity of IDPRs. (0) minimal disorder, (1) disordered termini, (2) disordered linker, (3) disordered 
loop, (4) disordered domain, (5) disordered protein with residual structure, (6) wholly disordered, collapsed protein, (7) 
wholly disordered, extended protein. Figure is reprinted with permission from (122). 
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Two extreme models have been proposed for the mechanism of coupled folding and 
binding (Fig. 2.5). In induced fit (IF), an IDP can stochastically explore its ensemble structure until  
it weakly associates with the binding partner, inducing subsequent folding (binding before folding) 
(126-130). In conformational selection (CS), the binding partner selects only a folded subset of 
the IDP ensemble that resembles the bound state (folding before binding) (127,131). Likely, 
MoRFs can utilize elements from both of these schemes, depending on the sequence 
characteristics, structural propensities, backbone dynamics, and environmental conditions (132-
134).  
Fuzzy complexes- IDPRs do not necessarily need to adopt secondary structures in order to be 
functionally relevant. Termed ‘fuzzy regions’, these IDPRs can remain disordered upon binding, 
have significant conformational heterogeneity, and are essential to the normal function of the 
protein or complex (135). Fuzzy regions can be functional through different structural 
mechanisms: they can adopt multiple, unrelated, resolvable conformations upon binding 
(polymorphic), serve as a linker between globular domains (clamp), provide extra context near 
existing binding sites (flanking), or remain mostly disordered and interconnect short motifs 
Figure 2.5: Models of coupled folding and binding. Top: conformational selection, bottom: induced fit. This figure is 
licensed for free use under a Creative Commons License (softsimu.blogspot.com)  
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(random). These regions can be further modulated by post-translational modifications or 
additional interactions.  
2.3  Functional Relevance of IDPs 
 A major realization in protein science is the observation that IDPs can have functions 
distinct from folded proteins, and therefore the presence of IDPs represent an evolutionary 
advantage (Fig. 2.6) (136). This is evident through observing increasingly complex organisms, 
which tend to have greater amounts of intrinsic disorder (137,138). The functional diversity and 
versatility that disorder confers allows for more complex signaling processes, and begins to 
provide an explanation as to how complex organisms can perform these processes without 
requiring any substantial increase in protein-coding genes (139). Here, I will provide a brief 
overview of the functions of intrinsic disorder, along with a detailed look of intrinsic disorder in 
three systems of interest to this particular dissertation: membranes, membrane proteins, and 
enzymes.   
2.3.1 General Functions 
 Because of their low hydrophobicity and high conformational dynamics, disordered 
regions are highly solvent accessible. This characteristic makes the side chains and backbone 
highly prone to post-translational modifications and proteolytic cleavage, respectively. This is 
Figure 2.6: Ordered and disordered proteins have distinct sets of functions. Disordered protein functions can 
broadly be classified into flexible ensembles (wholly disordered) and disorder-to-order transitions. Figure is adapted 
with permission from (136). 
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presumably because the dynamics of a disordered region can readily explore an enzyme’s active 
site until it is the correct orientation for catalysis to occur. Because of the strong correlation 
between protease sensitivity and site accessibility, limited proteolysis is a popular biochemical 
method to probe intrinsic disorder (140). PTMs such as phosphorylation can significantly affect 
the conformational dynamics of a disordered region, and can therefore affect function by tuning 
levels of folding and binding (141-144). 
 Disordered regions can also have other functions dependent on entropy. Often, a 
disordered region can serve as a long linker between globular domains or structural motifs, and 
the linker serves to increase frequency of collisions between the structured regions on either end. 
In these cases, the length of the linker is often directly correlated with the amount of 
conformational space that the other structured regions can explore. Besides length, many of the 
physicochemical factors discussed previously can affect factors such as the efficiency of the 
linker, including κ (level of compaction of the linker), PTMs, and sequence complexity. 
 The most notable function of IDPRs is in signaling, through interactions with 
macromolecules. Many of these interactions coordinated by disordered regions are highly 
promiscuous, serving as network ‘hubs’ in signaling (145). IDPs have several characteristics that 
make them well-suited to this role, such as binding with high specificity for multiple targets, low 
binding affinity, and fast dissociation rates on average. Several characterized hub proteins use 
these unique features to modulate allostery. In the case of the Phd/Doc toxin-antitoxin system, 
increasing Doc levels can turn transcription on or off by controlling Phd binding to its own operon, 
depending on biological threshold limits (146). Another case is the adenovirus early region 1A 
(E1A) protein, which can bind CREB binding protein (CBP) or retinoblastoma protein (pRb) at 
multiple sites. The interactions of this complex can either have positive or negative cooperativity, 
which depends on the availability of binding regions in E1A (147).  
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2.3.2 IDPs and Membranes 
 Proteins in general can coordinate interactions with the membrane bilayer in multiple 
different fashions. The interactions can be driven by either hydrophobic association (i.e. 
amphipathic helices) or lipid anchors, both of which would be able to embed inside the membrane 
to interact with the hydrocarbon core, ultimately deforming the membrane. Alternatively, proteins 
may interact with a headgroup through either structural specificity or electrostatic interactions, 
both of which would not be energetically favorable for bilayer penetration (Fig. 2.7). All of these 
types of interactions could be further facilitated through additional interactions with proteins 
embedded in the membrane. Though few protein-membrane interactions have been examined in 
the context of intrinsic disorder, reexamination of the literature suggests that many of the known 
protein-membrane interactions are coordinated by IDPRs, and therefore IDPRs can likely utilize 
these driving forces to different extents.  
In the case of general hydrophobic association, coupled folding and binding of 
amphipathic α-helices could drive protein-membrane association. This is supported mainly 
through studies of α-synuclein, which is natively disordered and adopts helical structure upon 
Figure 2.7. Models of peripheral protein-membrane interactions. (1) An amphipathic helix, (2) a hydrophobic loop, 
or (3) a lipid modification can be embedded in the membrane through hydrophobic association. (4) Electrostatic 
interactions between the protein and the membrane can be mediated by anionic phospholipids +/- divalent cations. This 
image is licensed for use under the GNU Free Documentation License (Wikimedia Commons).   
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binding to a phospholipid membrane, ultimately influencing membrane curvature (148-150). 
Alternatively, polyelectrolytic IDPRs could form fuzzy, transient complexes with a membrane, 
either directly through anionic phospholipid headgroups or indirectly through divalent cations. 
These type of interactions may create specificity for certain membrane compositions, including 
the cytoplasmic face of the plasma membrane, mitochondrial membranes, and outer bacterial 
membranes.  
Several disordered proteins including metenkephalin, myristoylated alanine-rich C kinase 
substrate (MARCKS), C1 domain-containing proteins can utilize both hydrophobicity and lipid 
specificity to promote membrane interactions (151-155). Other proteins such as α-synuclein and 
cytochrome c use more hydrophobicity or electrostatic forces, respectively (156-158). Some 
IDPRs use proteins embedded in the membrane to facilitate interactions, such as charybdotoxin, 
which occludes the pores of Shaker K channels, or ColE9, which threads through the porin OmpF 
(159,160).  
Intrinsic disorder could also indirectly facilitate membrane association through co-
translational or post-translational lipidation. As other modifications such as phosphorylation are 
highly correlated with disordered regions (142), it is likely that the same principles apply to lipid 
modifications, though they have not been examined in the literature. Extensive analyses would 
be challenging for lipidations such as prenylation and palmitoylation, as these modifications occur 
on cysteines. These represent troublesome residues for disorder predictors, as they are generally 
biased towards order due to disulfide bonding propensity, combined with the fact that disorder 
predictors do not consider cellular context.  
2.3.2 IDPs in Integral Membrane Proteins 
 A few computational studies have examined IDRs and specific features such as MoRFs 
in the integral membrane proteome, generally observing that IDRs often occur in the termini or 
the loops (161-164). Relatively few experimental studies have examined functional IDRs in 
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membrane proteins, likely because of the technical challenges associated with probing membrane 
protein function. However, it is clear that there are diverse functional implications.  
 While MoRFs can be observed computationally in membrane proteins, very few of these 
have been experimentally validated and functionally characterized. An intrinsically disordered C-
terminus of E-Cadherin folds upon binding to β-catenin, which is ultimately important for the 
assembly of an F-actin-associated complex (165,166). A MoRF in the Na+/H+ exchanger, NHE1, 
is responsible for its localization to the plasma membrane through unknown biochemical 
mechanisms (167). Disordered termini can also function as linkers. The Shaker Kv channel has 
an intrinsically disordered C-terminus containing a PDZ-binding motif at the end. This disordered 
linker is able to explore a large amount of conformational space to promote interaction with the 
PDZ-binding motif with PSD-95 (168,169). This functions similar to a fishing rod, where the length 
of the linker appears to be optimized for PSD-95 interaction.  
2.3.3 IDPs in Enzymes 
 As the induced-fit model of enzymes would suggest, a fundamental aspect of enzyme 
catalysis is that it requires a semi-rigid active site for maximum efficiency, presumably to 
selectively stabilize a transition state over the substrate. For most observed enzymes, 
maintenance of rigidity in the active site requires well-folded structural domains. However, a few 
exceptions to this rule have been observed, where either fully disordered, partially disordered, or 
inducibly disordered enzymes can still have physiologically relevant rate constants (170). The 
effect of intrinsic disorder on enzyme function can be broadly classified into those that directly 
affect catalysis, and those that affect regulation.  
Enzymes can have significant structural disorder in their active site, where the rigidity of 
active site residues is maintained by bound divalent metal cations. Folding intermediates and non-
native induced disordered states of enzymes have been observed to have activity, such as the 
cases of bacterial acylphosphatases (171), topoisomerase I (172,173), 5-aminolevulinate 
synthase (174), adenylate kinase (175), and RNase T1 (176). While the overall relevance of 
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induced disordered states is not immediately clear, it is possible these states might be important 
for adaptation to variations in intracellular and extracellular environments (e.g., pH, salinity, and 
temperature), and may generally suggest high evolutionary potential.  
Well-ordered enzymes can also have disordered regions distant from the active that are 
responsible for enzyme regulation in the cell. These regions generally serve as scaffolding/hub 
regions for protein-protein interactions. IDPRs can also serve as linkers for regulatory domains or 
other functional elements, as in the case of Yck2, which has a long glutamine-rich linker between 
the kinase domain and the palmitoylated region (177). This linker is proposed to facilitate a 
coupled interaction of these two regions with Akr1, the cognate palmitoylation enzyme.  
2.4 Closing Remarks 
 IDPRs represent an exception to the structure-function paradigm, as they still have 
biological function without ordered structure. They represent a significant portion of the proteome, 
and have many unique physicochemical properties. These unusual behaviors result in functions 
distinct from those of ordered proteins, and primarily involve processes related to signaling and 
recognition. While there are a limited number of studies, disordered regions in highly structured 
proteins such as membrane proteins and enzymes can have interesting regulatory properties. I 
hypothesize that by using the computational and biophysical toolkit of IDPRs, I can learn more 
about the regulation and function of transmembrane palmitoylation enzymes and substrates.  
2.5 Central Hypothesis 
 Through my first two chapters, I have described palmitoylation as a poorly understood yet 
important and interesting regulatory process, and the idea that intrinsic disorder can provide an 
alternative conceptual framework to understand the structure and function of proteins. By applying 
the conceptual framework of intrinsic disorder to palmitoylation enzymes and substrates, I 
propose that we can achieve a greater understanding of the palmitoylation process. First, I will 
focus on palmitoylated substrates, where we found that among other factors, classification of 
protein regions based on intrinsic disorder state led to robust prediction of palmitoylated sites. 
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Next, I will discuss my findings regarding a conserved MoRF in the C-terminus of PATs that 
appears to participate in enzyme function. Finally, I will discuss the molecular defect of the XLID-
associated gene zDHHC9, caused by removal of a non-conserved, disordered region.  
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CHAPTER 3 
 
Physicochemical Sequence Characteristics that Influence S-Palmitoylation Propensity 
 
3.1 Note to Reader 
Portions of this chapter have been previously published in JBSD (2016) 1-14 and have 
been reproduced with permission from JBSD (Appendix A) (178). 
3.2 Introduction 
 Several thousand new palmitoylated substrates have been experimentally identified by 
deploying methods such as ‘click’ chemistry and acyl-biotin exchange on specific organisms, 
subcellular compartments, cell types, and other classifications. This increase in known substrates 
has led to comprehensive compendiums of palmitoylated proteins, which will surely be essential 
for future development of the field (46,47). Despite these innovations, a clearly recognizable 
palmitoylation ‘motif’ has not been identified, as is the case for other types of lipidation. 
 The large number of proteins that undergo palmitoylation, along with the large family of 
palmitoyltransferase enzymes, may contribute to the difficulty of identifying a simple consensus 
sequence. It also suggests that a more sophisticated search algorithm must be developed that 
takes into account more than primary sequence, also including factors such as subcellular 
localization, membrane topology, secondary structure, and other physiochemical properties of a 
polypeptide chain.  For example, cysteines both within and adjacent to transmembrane domains 
appear to be prone to palmitoylation (38). In addition, prior farnesylation and myristoylation 
promote sequential palmitoylation of proximal cysteines, such as with Ras and Gα, respectively 
(8,179). Overall, it appears that while PATs may have some inherent specificity towards 
substrates, there may be overlap between related zDHHC PATs (19,59,180). However, attempts 
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to determine whether individual zDHHC enzyme or sub-families of zDHHC enzymes recognize 
common targets have had limited success. The development of better computational tools, along 
with larger data sets of experimentally determined palmitoylated proteins should clarify whether 
zDHHC-dependent consensus sequences and/or recognition features exist.   
 In this study, we use a carefully selected and manually curated dataset of palmitoylated 
cysteines to characterize the physicochemical properties that define the surrounding environment 
of palmitoylatable residues. We find that the likelihood of a cysteine to be palmitoylated is 
dependent not only on its membrane association state and structural context, but also on its 
surrounding sequence composition. Inclusion of context-based information led to the 
development of a palmitoylation predictor that outperforms existing predictors on unbiased data 
sets. Overall, we hypothesize that these observations will not only lead to improvements in 
palmitoylation prediction, but also a better understanding of the complex dynamics between PATs 
and their substrates. 
3.3 Construction and Composition of a Dataset of Palmitoylated Proteins 
  The final dataset consists of 244 proteins containing 473 P sites and 1973 NP sites. These 
sites were further subdivided into transmembrane (TMP) versus non-transmembrane (Non-TMP) 
based on the annotated membrane association state of the protein. Finally, the sequences of the 
TMP were further subdivided based on TMHMM 2.0 predictions, where cysteines were predicted 
to be either within a transmembrane helix (TMhelix), predicted to be luminal facing (TMP-OUT), 
or predicted to be cytosolic facing (TMP-IN). The distribution of the dataset across organisms is 
skewed towards vertebrates, with 192/244 of the sequences falling under this category. The final 
composition of the dataset after assembly and annotation is graphically represented in Fig. 3.1.  
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Examination of our entire dataset using a WebLogo suggests that there is no inherent sequence 
bias around cysteines independent of palmitoylation (Fig. 3.2A) 
3.4 Sequence Analysis of Palmitoylated Proteins 
3.4.1 Sequence composition directly surrounding cysteines influences likelihood of 
palmitoylation  
  Analysis of our entire dataset using a two-sample WebLogo (2SWL) revealed an apparent 
enrichment of hydrophobic residues on the amino side, and basic residues on the carboxyl side 
of palmitoylated cysteines (Fig. 3.2B). Further separation of our entire dataset based on 
transmembrane association state reveals that this physicochemical contribution appears to be 
specific to transmembrane proteins (Fig. 3.2C) but not cytosolic proteins (Fig. 3.2D), which is in 
agreement with a previous study (46). 
SubclassClassSites Proteins 
244 
proteins
473 P 
sites  
229 TMP 
sites 
147 sites 
TMP-IN
41 sites 
TMP-OUT
41 sites 
TMHELIX
244 Non-
TMP sites 
1973 NP 
sites  
1169 TMP 
sites 
208 sites 
TMP-IN
720 sites 
TMP-OUT
241 sites 
TMHELIX
804 Non-
TMP sites 
Figure 3.1. Characteristics of the entire data set. Flowchart of transmembrane filtering of palmitoylated substrates 
according to likely palmitoylation state (P, NP), membrane association state (TMP, NON -TMP), and predicted 
transmembrane helix orientation (TMhelix, TMP-OUT, TMP-IN).  
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3.4.2 Cysteine position relative to a transmembrane helix determines physicochemical 
properties of regions surrounding palmitoylatable sites  
  To investigate more closely the apparent ‘sidedness’ of hydrophobic and basic residues, 
we further parsed the TMP set using a combination of UniProt annotation and the TMHMM 2.0 
algorithm (described further in Methods), which predicts transmembrane domains as well as 
orientation of a protein relative to the lumen and cytosol. Cysteines located within a predicted 
transmembrane helix (TMhelix) displayed a greater ratio of carboxyl-terminal basic residues 
compared to amino-terminal hydrophobic residues (Fig. 3.3A), with this enrichment being 
significantly greater than that of the TMP set.  
  The predicted cytosolic (TMP-IN) set was used as a comparison to the TMhelix set, as the 
ratio of P/NP sites were more significant in the TMP-IN set compared to the predicted luminal 
(TMP-OUT) set (0.71 to 0.06, respectively). This ~12.4 fold increase in ratio is likely reflective of 
the relevance of biological context, since cytosolic proteins are palmitoylated whereas luminal 
proteins are not. Within the TMP-IN set, there is a clear increase of enrichment of hydrophobic 
residues on the amino-terminal side of the site, whereas the predominance of basic residues on 
the carboxyl-terminal side not only appears to be greatly depleted, but also dampened by the 
Figure 3.2: Properties of residues surrounding palmitoylated sites. (A) represents the distribution of the entire 
dataset using a WebLogo with a Y-axis of two different lengths. (B) 2SWL analysis of the entire dataset, which containes 
473 P sites and 1973 NP sites. (C) 2SWL analysis of the TMP data set, which consist of 1169 NP sites and 229 P sites. 
(D) 2SWL analysis of the NON-TMP data set, which consists of 804 NP sites and 244 P sites. 
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presence of residues with different physicochemical properties (Fig. 3.3B). In other words, 
cysteines prone to palmitoylation within a transmembrane protein will either have surrounding 
basic or hydrophobic residues, and this is dependent on whether or not the cysteine is within a 
transmembrane helix. 
  It should be noted that in these datasets, there are instances that have surrounding 
sequence patterns that are reverse of what would be predicted by our results (i.e. amino-terminal 
basic residues and carboxyl-terminal hydrophobic residues). This is readily explained by taking 
into consideration that cytosolic-facing, juxtamembrane cysteines can occur before or after the 
TMD in the primary sequence, depending on the transmembrane topology of the protein. 
3.4.3 Palmitoylated cysteines associated with myristoyl/prenyl modifications likely have 
no additional physicochemical properties that contribute to palmitoylation 
propensity 
 It is well-known that peripheral lipid modifications such as myristoylation and prenylation 
can promote palmitoylation of nearby cysteines. However, it is unclear if surrounding sequence-
based characteristics influence likelihood of palmitoylation in the presence of other lipidations. 
The N-DIS and C-DIS displayed minimal enrichment with regards to local amino acid composition, 
besides the presence of myristoylation and prenylation motifs (MGC- and -CaaX, respectively) 
which are known to promote palmitoylation (data not shown).  
  These sets were further divided into myristoylated and prenylated P sets, as no NP 
cysteines were found at the predicted N-terminus of myristoylated or prenylated proteins. In these 
Figure 3.3: Enrichment of sequences surrounding cysteines is dependent on proximity to a transmembrane 
domain. (A) 2SWL analysis of the TMhelix data set, which consists of 241 NP sites and 41 P sites. (B) 2SWL analysis 
of the TMPIN sets, which consists of 208 NP sites and 147 P sites. 
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cases, sequences were aligned to the myristoyl or prenyl motifs, rather than a putative 
palmitoylated cysteine, in order to determine if there was a relationship between 
myristoylation/prenylation and putative palmitoylated cysteines. In these sets, there are still no 
significant physicochemical features displayed. Additionally, the palmitoylated cysteine appears 
to be more conserved when located closer to the myristoylated/prenylated residue (Fig. 3.4A and 
3.4B, respectively), indicating there may be a correlation between palmitoylation likelihood and 
distance to the myristoyl or prenyl modification. 
 
3.5 Development of a Palmitoylation Predictor 
3.5.1 Improvement of predictive accuracy by incorporation of physicochemical factors, 
contextual classification, evolution, and dataset annotation 
  As classification of sites into categories revealed trends in physicochemical properties of 
surrounding sequence, we hypothesized that these annotations would significantly improve 
accuracy of palmitoylation algorithms. Using our manually curated data set, classifications of 
membrane association and disorder propensity, values for secondary structure/electrostatic 
charge/average surface area (181,182), ModPred palmitoylation output values (183), and 
position-specific scoring matrix values (184), we created a predictive model based on a simple 
logistic regression learning algorithm. Based on the 22 selected features (Table 3.1), our predictor 
accounts for some but not all of the annotations that we hypothesized were important, most 
significantly sidedness of charge/hydrophobicity and the predicted transmembrane position 
(TMP-OUT). The previously discussed ratio of P/NP sites between the TMP-IN and TMP-OUT 
Figure 3.4: Correlation of myristoylation and prenylation motifs to the composition of nearby palmitoylated 
cysteine sites. (A) WebLogo analysis of 23 myristoylated proteins that are also classified as N-DIS and 
palmitoylated. (B) WebLogo analysis of 17 prenylated proteins that are classified as C -DIS and also palmitoylated. 
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sets made the presence of this factor unsurprising, indicating that simply considering the context 
of a cysteine in the cell may be a powerful predictive factor. A notable absence is myristoyl/prenyl 
motifs, which we assume to be the case because of the relatively low presence of these proteins 
in our training set (24 and 17 proteins, respectively). More notable absences are TMhelix and 
TMP-IN as predictive factors, which may be due to either redundancy in training data (i.e. 
secondary structure as an indicator of TMDs), or simply weak correlations that require refinement. 
Future predictors may consider creating separate models for proteins predicted to undergo 
additional lipid modifications, integral transmembrane proteins, and peripherally-associated 
membrane proteins.  
 
 
Table 3.1: A combination of the 22 minimal physicochemical, evolutionary, and classification features of 
cysteines and their surrounding residues that contribute to palmitoylation prediction of our predictor 
described in this study. For a given 21-mer, the cysteine is at position #11, the first residue is position #1, and the 
last residue is position #21. 
 
Feature  Properties  Source Reference 
BF: 8 Secondary Structure (Factor II) of 
amino acid #8 
N/A (182) 
EF: 6, 16  Electrostatic Charge (Factor V) 
amino acid #6, #16 
N/A (182) 
ORD Classification Tag PONDR-FIT, this study (185) 
C-DIS Classification Tag PONDR-FIT, this study (186) 
TMP-OUT Predicted Transmembrane 
Position   
TMHMM 2.0 (187) 
ASA: 7 Average surface area of amino 
acid #7  
NetSurfP (181) 
Beta: 2, 6 Propensity for beta sheets at the 
#2, #6 residue  
NetSurfP (181) 
Coil: 5, 15 Propensity for coil sheets at #5, 
#15 residue 
NetSurfP (181) 
ModPred Score 
(PSSM) 
ModPred final score for 
palmitoylation 
ModPred (183) 
PSSM: 16, 21, 
26, 46, 56, 77, 
94, 100, 140, 
145 
Raw PSSM scores (out of 164 
evolutionary features) 
PSI-BLAST (183,184) 
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3.5.2 Comparison of our Model to Existing Predictors 
  To determine the overall predictive ability of our algorithm, we used the Matthews 
Correlation Coefficient (MCC) value determined by 10-fold cross validation, which provides a 
value from -1 (completely imperfect prediction) to 1 (perfect prediction), with 0 being random 
prediction. In 10-fold cross-validation, the dataset is randomly separated into 10 equally sized 
subsamples. 9 subsamples are used for training, and 1 sample is used for testing. This process 
is repeated 10 times (folds), and the final output values are the average of the 10 folds. A more 
detailed explanation of the terms used hereafter can be found in the Methods section (Model 
training and feature selection). Our predictor achieved a Matthews Correlation Coefficient (MCC) 
of 0.74 via 10-fold cross validation (Table 3.2), a marginally higher value than two recently 
published predictors, WAP-Palm and PalmPred (188,189), which were reported to achieve 0.73 
and 0.71, respectively.  
Table 3.2: 10-fold cross validation values of the new predictive algorithm described in this study. 
10-fold cross validation Value 
Sensitivity 0.732 
Specificity 0.967 
Accuracy 0.922 
MCC 0.739 
 
  However, MCC values can be easily biased by similar or redundant proteins in the dataset 
– in other words, the same site could potentially be found in both the training and testing sets. 
Therefore, a better method to compare predictive capability between algorithms is to use proteins 
that none of the algorithms have been trained on. To make a more accurate comparison between 
predictors, we tested 13 proteins not used for the training of any published predictor, including 
our own. Our observations are limited by the size of our dataset, which is an unavoidable issue 
as relatively few unique palmitoylated proteins have been described that have not been used for 
training of any algorithm. To account for the fact that other predictors do not consider other 
modifications of cysteines, we did not remove disulfide-bonded and prenylated cysteines from our 
40 
 
testing datasets. We found that our algorithm performed significantly better than published 
predictors, with a 0.43 and 0.34 increase in MCC over WAP-Palm and PalmPred, respectively 
(Table 3.3).  
 
Table 3.3: Comparison of the new predictive algorithm to existing predictors. Predictions of disulfide-bonded and 
prenylated cysteines are included in these datasets. The initial 13 proteins consist of 18 P sites and 88 NP sites. RyR 
consists of 18 P sites and 82 NP sites.  
Tool 
13 proteins 13 proteins + RyR1 
Sensitivity (true 
positive rate) 
Specificity (true 
negative rate) 
Accuracy 
(Sn+Sp) 
MCC MCC 
CSS-Palm 
4.0 0.50 0.91 0.84 0.42 0.18 
WAP-Palm 0.50 0.65 0.62 0.11 0.04 
ModPred 0.44 0.83 0.76 0.25 0.17 
PalmPred 0.22 0.93 0.81 0.20 0.06 
This study 0.44 0.98 0.89 0.54 0.34 
 
 
  We then directly compared our output when considering these 13 proteins to the outputs 
of CSS-Palm 4.0, WAP-Palm, PalmPred, and ModPred. These outputs are provided in a 
supplementary table. In this limited dataset, our predictor outperforms others by having a similar 
if not better true positive (sensitivity) rate as others and a slightly higher true negative (specificity) 
rate, while maintaining a relatively low false positive rate (Table 3.3). When predictions of 
individual sites are compared to those of the most-cited predictor in the field (CSS-Palm) and one 
of the more recently published predictors (PalmPred), it can be seen that the true negatives 
predicted are mostly common between predictors, while there is variation between true positive, 
false positive, and false negative predictions. Again, these comparisons suggest our predictor is 
an improvement through relatively low false positive rates, slightly higher true negative rates, and 
similar or better true positive rates (Fig. 3.5). 
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  Interestingly, our results changed dramatically upon inclusion of a unique protein, the 
ryanodine receptor (RyR1). RyR1 likely represents a challenge for present palmitoylation 
predictors, as it is a multipass transmembrane protein that is extremely large (~5000 amino acids) 
and contains many cysteines (18 P, 82 NP) that undergo palmitoylation as well as S-oxidation 
and S-nitrosylation due to reactive oxygen and nitrogen species (27). Including the RyR in our 
testing set significantly decreased all MCC values, suggesting that more factors may have to be 
considered for optimal predictive accuracy (Table 3.3).  
3.6 Discussion 
 It is widely assumed that S-palmitoylated substrates, unlike those of many other post-
translational modifications, lack a recognizable consensus motif. While studies have identified 
Figure 3.5: Comparison of predictors on the unbiased 13 protein testing set. The Venn Diagrams represent the 
(A) true positive, (B) true negative, (C) false positive, and (D) false negative rates of PalmPred (orange, bottom left), 
CSS-Palm 4.0 (green, bottom right), and the predictor described in this study (blue, top middle). The area of each 
circle is directly proportional to the total number of sites within each circle.  
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residues proximal to palmitoylated cysteines that appear critical for efficient palmitoylation 
(73,190), a single consensus sequence has not emerged. This has led some to conclude that 
palmitoylation is promiscuous and there is no sequence preference (19). Another possibility is 
that physiological context, with or without sequence specificity, dictates the likelihood of 
palmitoylation (68). For example, cysteines adjacent to transmembrane domains appear to 
increase the propensity of a cysteine being palmitoylated. 
In this study, we addressed these questions using computational techniques. First, we 
constructed a high-quality dataset of palmitoylated proteins through an exhaustive critical analysis 
of the literature, similar to the publicly available database SwissPalm (46). This dataset only 
consisted of unique proteins with very well-characterized palmitoylated sites, using a set of 
guidelines comprehensible and reasonable to the experimental biologist. Secondly, working 
under the hypothesis that perhaps there are differential characteristics guiding palmitoylation, we 
divided this dataset into different groups based on predicted and known structural and spatial 
context. While we assume that our dataset is appropriately distributed among the many types of 
palmitoylated proteins, the distribution is biased by the limits of the techniques in the field. The 
majority of palmitoylated sites in our data set were identified by 3[H] palmitate, which lacks the 
sensitivity of more recent techniques such as acyl-biotin exchange (ABE), and therefore our 
dataset may be biased against transient or less favorable sites (45,191,192). Additionally, 
identified sites are not certain to be physiologically relevant, as the identification techniques used 
throughout the literature are generally based on the non-physiological conditions of enzyme-
substrate overexpression analysis (61). Nevertheless, these exceptions likely represent a minor 
fraction compared to the entire dataset.  
Palmitoylated cysteines in transmembrane proteins appear to be enriched in both amino-
terminal hydrophobic and carboxyl-terminal basic residues. We will discuss our results in the 
context of cytosolic cysteines carboxyl-terminal to a transmembrane domain, since our dataset 
appears to be skewed toward those instances. Our results suggest that the surrounding sequence 
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of a palmitoylated cysteine found in a predicted transmembrane helix tend to be enriched in 
primarily basic residues, whereas palmitoylated cysteines outside of TMDs are enriched in 
primarily hydrophobic residues. The most likely reason for this difference may be because 
palmitoylated cysteines predicted to be within the transmembrane helix are specifically 
juxtamembrane, and the adjacent residues promote palmitoylation through interaction with the 
zDHHC PAT, membrane interactions, or some other mechanism. This mechanism has been seen 
in reovirus p10, which requires basic residues adjacent to the palmitoylated cysteine for p10-
mediated membrane fusion (70). Alternatively, basic residues could alter the accessibility of the 
cysteine to the zDHHC PAT catalytic cysteine-rich domain (CRD). Since polar residues within 
transmembrane helices contribute to charge-charge repulsions or interactions (193), loose helix 
packing of multipass transmembrane proteins through repulsions of positively charged residues 
may increase accessibility of the cysteine to the CRD, which may be partially embedded in the 
membrane bilayer to prevent hydrolysis of the autopalmitoylation state by water (77,83). 
Conversely, cysteines outside of transmembrane domains could be enriched in hydrophobic 
residues because they are either near a TMD, or require helix-promoting residues for either 
recognition or membrane-binding.   
In the case of cysteines proximal to myristoylated and prenylated sites, no amino acid 
preference emerged in our results. The only noticeable information that could be extracted was a 
greater conservation of cysteines closer to the myristoyl/prenyl motif of the palmitoylated protein. 
Interestingly, no non-palmitoylated cysteines were found that were predicted to be at the 
disordered N-terminus of a myristoylated protein, or that were at the disordered C-terminus of a 
prenylated protein. Taken together, we hypothesize that the presence of a myristoyl or prenyl 
motif is sufficient to promote palmitoylation of a nearby cysteine. Consistent with this hypothesis, 
it has been previously observed that alterations of residues flanking the palmitoylated cysteines 
of H-Ras have no effect on the palmitoylation state (194). However, these mutants did not 
correctly localize to the plasma membrane, indicating there may be some targeting function of 
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these residues independent of palmitoylation. Also in H-Ras, a mutant H-Ras which is 
myristoylated but not farnesylated is still a substrate for palmitoylation, and properly localizes to 
the plasma membrane (15), perhaps hinting that the exact chemical composition of the prior lipid 
modification is not especially important. 
 While cytosolic palmitoylated proteins were not a primary focus of this study, an interesting 
future direction of this work will be determining physicochemical parameters of these proteins. 
Our studies in peripherally-bound membrane proteins suggest that properties promoting 
membrane association are critical in determining palmitoylation propensity. One possibility is that 
cytosolic proteins may be weakly interacting with membranes, through transient secondary 
structure and/or electrostatic interactions, a phenomenon seen with intrinsically disordered 
proteins such as α-synuclein (149). This hypothesis is supported by a number of studies in the 
Ras family of GTPases. In the case of Saccharomyces cerevisiae Ras2, methods of membrane 
association appear interchangeable – replacement of the C-terminal Ras2 farnesylation motif (-
CIIS) with a nonprenylated mutant rich in hydrophobic and basic residues (-CIIKLIKRK) is able to 
complement the loss of Ras2 (195), and a similar result is observed in mammalian H-Ras (196). 
 Through our studies and various observations in the literature, we propose a model where 
in order for most proteins to be palmitoylated, it requires an initial membrane association in order 
to increase the likelihood of interacting with an active zDHHC enzyme (Fig. 3.6). This would 
suggest that most, if not all palmitoylated proteins are either juxtaposed to or within 
transmembrane domains, located near previously lipidated residues, or are surrounded by 
hydrophobic and/or basic residues which would likely have affinities toward phospholipid 
membranes. After this initial membrane association, there are multiple possibilities – either the 
protein is palmitoylated stochastically by the closest available enzyme, the enzyme specifically 
palmitoylates the protein through a substrate recognition mechanism, or a balance between both. 
Previous research supports all of these possibilities. Redundancy of PATs has been documented 
– knockdown of zDHHC9, a PAT specific for H-Ras and N-Ras when using recombinant protein 
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(197), did not significantly affect H-Ras membrane association kinetics in HeLa cells (19), 
supporting a model of stochastic palmitoylation where any PAT can palmitoylate any substrate. 
Conversely, substrate recognition sequences have been found on a few PATs, such as the 
ankyrin repeats of zDHHC13 and zDHHC17 (72,198), or the PDZ-binding motif of zDHHC8 
(74,199). However, it remains to be seen if these are a general phenomenon of zDHHC PATs, or 
simply outliers which recognize sequences distant to residues surrounding palmitoylated 
cysteines. 
 
 We have applied our findings toward the improvement of S-palmitoylation predictive 
algorithms. Several algorithms already exist and have increased in predictive accuracy over time 
(183,188,200,201), but most do not account for the structural and spatial parameters we have 
proposed. In general, our predictor appears to predict palmitoylated sites with a similar or better 
Figure 3.6: A decision tree model of factors that influence S-palmitoylation propensity of non-luminal cysteines 
in eukaryotes. Likelihood of other cysteine modifications and enzyme regulation factors are not considered in this 
model.  
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rate than other predictors, while avoiding overprediction of palmitoylation, shown by the lower 
false positive rate. Therefore, overall predictive capability towards unique palmitoylated proteins 
appears to increase when a combination of structural and spatial contexts, sequence 
enrichments, and manual curation are taken into account. Which combination of these factors is 
most important is unclear at this time; however, we expect that future iterations of palmitoylation 
predictors will continue to be improved by including only experimentally validated and curated 
datasets such as SwissPalm (46). Additionally, the extremely poor prediction of the unique RyR1 
protein suggest that new factors may also need to be considered, such as propensity of S-
nitrosylation and S-oxidation due to proximity of the mitochondria. These technical and contextual 
considerations, combined with continued investigation of the physicochemical properties of 
palmitoylated cysteines and zDHHC PAT regulation, should lead to better understanding of 
palmitoylation.  
 
3.7 Experimental Procedures 
3.7.1 Dataset assembly 
  Our dataset was compiled by retrieving palmitoylated proteins from UniProt and CSS-
Palm 4.0 (201). Palmitoylated proteins from the UniProt database (release 2013_10) were 
composed by searching the keywords ‘Sequence annotation [FT]’ under “Field”, ‘Lipidation’ under 
“Topic”, ‘S-palmitoyl cysteine’ under “Term”, and ‘Experimental’ under “Confidence”. After 
duplicates were removed, an 80% sequence identity cutoff was implemented using the ElimDupes 
web server in order to remove redundant proteins. Cysteines +/- 10 amino acids were extracted, 
and another 90% sequence identity cutoff was implemented at the 21-mer level in order to 
eliminate remaining redundancy. Sites were manually divided into palmitoylated (P) and non-
palmitoylated (NP) sets, based on the following requirements: 
 Palmitoylation must be directly labelled, through either [3H] palmitate incorporation, 
ABE-based methods, ‘Click’ chemistry, or other experimental methods 
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Studies where cysteine mutation led to change in localization, gel shift other than acyl-
PEGyl exchange, or other method not directly relevant to palmitoylation were not 
considered. While the sensitivity of direct detection of palmitoylation varies by method, we 
believe that these differences are likely to have minimal impact.  
 Proteins must be S-palmitoylated, shown by either hydroxylamine cleavage or 2-
bromopalmitate inhibition 
Several instances of palmitoylation occur via different mechanisms, involving enzymes 
other than zDHHCs and linkages other than thioesters. In this study, we were only 
interested in zDHHC catalyzed, thioester-linked palmitoylation. For our purposes, either 
hydroxylamine cleavage (demonstrates thioester linkage) and/or 2-BP inhibition 
(demonstrates probable zDHHC catalysis) was considered sufficient. 
 Specific palmitoylated sites must be validated experimentally 
Instances where multiple cysteines were mutated simultaneously were not included, 
unless the sites were within three residues of one another. 
 Palmitoylation must not be detectable when all known palmitoylated cysteines are 
mutated 
If mutation of a subset of cysteines on a protein of interest still had detectable 
palmitoylation levels, it is possible that other cysteines on the protein may also be 
palmitoylated, which would therefore bias the NP set. 
 Previously modified cysteines are not included 
As S-palmitoylation does not occur in the lumen, all disulfide-bonded cysteines that were 
both annotated by UniProt and predicted by CYSPRED (202) were removed in order to 
reduce bias in our negative data set. Prenylated cysteines were also excluded from our 
dataset. 
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  Although these rules may miss some palmitoylated sites due to experimental variation, 
they likely represent the highest possible stringency while retaining enough proteins for the 
analysis.  
3.7.2 Annotation 
Membrane association state - Proteins that are lipidated are more likely to undergo sequential S-
palmitoylation. Therefore, known palmitoylation-promoting modifications such as N-myristoylated 
glycines (N-terminal, MGC motif) and prenylated cysteines (C-terminal, -CaaX box) were 
annotated. While O-palmitoleoylation is known to promote subsequent S-palmitoylation in 
proteins such as Wnt, these were not annotated, as secreted proteins undergo a different 
mechanism of palmitoylation (1). Additionally, palmitoylation occurs at integrally associated 
membrane proteins, often directly adjacent to a TMD. We applied the TMHMM 2.0 algorithm to 
our datasets (187), crosschecked this analysis with UniProt annotations of subcellular localization, 
and classified each protein as either not transmembrane (NONTMP) or transmembrane (TMP). 
Within the TMP set, sites were classified according to the output of TMHMM 2.0, which factors 
the probability that the N-terminus is on the cytoplasmic side of the membrane. Therefore, the 
correct number of TMDs and the orientation of the termini is predicted with reasonable accuracy, 
with some exceptions occurring due to factors such as signal peptides being mistaken for TMDs 
or reversed direction of a protein with only one TMD. Based on the TMHMM 2.0 output, the TMP 
set was further subdivided into: within the helix (TMHELIX), predicted to be cytosolic (TMP-IN), 
or predicted to be organelle luminal or outward facing (TMP-OUT). 
Intrinsic disorder features - Structural characteristics such as intrinsic disorder have been 
implemented into palmitoylation prediction algorithms with varying success (188,203). However, 
we hypothesized that accurate intrinsic disorder predictors may help generalize aspects of 
structural context. Therefore, we utilized outputs from PONDR-FIT (185), a highly accurate 
metapredictor which incorporates the outputs of FoldIndex (204), TopIDP (205), PONDR® VLXT 
(108), PONDR® VSL2 (206), PONDR® VL3 (207), and IUPred (208).  
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  All cysteines were broadly classified based on their intrinsic disorder status (Fig. 3.7). For 
a given protein, intrinsically disordered (>0.5) residues from the first instance until the first instance 
of an ordered residue were considered to be the N-terminal tail (N-DIS). The reverse principle 
was used for the C-terminal tail (C-DIS); that is, intrinsically disordered residues from the last 
residue towards the amino terminus, until the first instance of an ordered residue. Cysteines within 
the remaining internal residues were further classified based on predicted intrinsic disorder, where 
sites with a disorder score of greater than or equal to 0.5 were considered ‘disordered middle’ (M-
DIS), whereas sites less than 0.5 were considered ‘ordered’ (ORD). 
 
Disulfide bond filtering - Cysteines identified as disulfide-bonded by both UniProt annotations and 
CYSPRED prediction (202) were removed from the dataset. This filter removed 0 cysteines from 
the P set and 592 cysteines from the NP set, which was expected considering our initial 
assumptions.  
Figure 3.7: Classification of predicted termini based on disorder score. In this model PONDR-FIT plot (Ras2, 
UniProt ID: P01120), all sites until the first red tick mark were considered N-DIS, all sites until the next red tick mark 
were considered ORD or M-DIS (if the site had a disorder score less than or greater than 0.5, respectively), and all 
sites after were considered C-DIS. 
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3.7.3 Analysis 
WebLogo - The WebLogo software is able to generate graphical representations of consensus 
sequences (209,210). The default values were generally used, with minimal exceptions. The 
default color scheme based on chemical properties was used, where small/polar residues (G, S, 
T, Y, C) are green, neutral residues (Q, N) are purple, basic residues (K, R, H) are blue, acidic 
residues (D, E) are red, and hydrophobic residues (A, V, L, I, P, W, F, M) are black.  
Two-sample logos - The two-sample WebLogo (2SWL) was utilized in order to display the 
differences between P and NP sets (211). In this tool, residues are separated into two groups: (a) 
enriched in the P set, or (b) depleted in the P set. The color scheme used was the WebLogo 
default mentioned previously. Statistically significant residues are displayed proportionally to the 
difference between the two sets. The p-value was calculated using a t-test, and p-values 
calculated via binomial distribution did not yield significantly different results (data not shown). 
Composition profiler - In order to determine the differences of physicochemical properties 
between the P and NP sets, the Composition Profiler tool was used (212). Like the two-sample 
logo, this tool displays differences between two datasets, except using specific amino acid 
physicochemical properties such as charge, hydrophobicity, size, and flexibility. 
Model training and feature selection - For design of a predictive algorithm, the open-source WEKA 
tool was used (213). Default values were generally used unless otherwise specified. The 
‘SimpleLogistic’ (linear regression) classifier was used, although different classifiers did not yield 
significantly lower values.  
  Generally, the output of a predictor can have four potential output values: known 
palmitoylated cysteine is predicted to be palmitoylated (true positive, TP), known not-
palmitoylated cysteine is not predicted to be palmitoylated (true negative, TN), known 
palmitoylated cysteine is not predicted to be palmitoylated (false negative, FN), and known not-
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palmitoylated cysteine is predicted to be palmitoylated (false positive, FP). These values can be 
interpreted in several different ways: Sensitivity is the true positive rate (TP / [TP + FN]), specificity 
is the true negative rate (TN / [FP + TN]), and accuracy is the combination of sensitivity and 
sensitivity ([TP + TN] / [TP + TN + FP + FN]). The Matthews Correlation Coefficient (MCC) is 
generally regarded as the most balanced measure of predictive capability, and can be 
represented by the equation below. The resulting value is from -1 to +1, where -1 is completely 
imperfect prediction, 0 is completely random prediction, and 1 is completely perfect prediction.  
  We began with 356 features in our dataset, which included per-residue and cumulative 
scores of cysteines and surrounding residues (106,181,182,185), classification tags annotating 
structural context (185,187), binary myristoylation/prenylation annotation, evolutionary features 
(184), and a previous palmitoylation predictor (183). The entire list is available upon request. We 
performed feature selection using the in-built Weka attribute evaluator ‘CfsSubsetEval’ and 
search method ‘Exhaustive’. 
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CHAPTER 4 
 
The Structure and Function of a Conserved C-Terminal Region in Erf2 
 
4.1 Introduction 
 zDHHC PATs are characterized by a number of conserved features: 4-6 transmembrane 
(TM) regions, a 51 amino acid catalytic cysteine-rich domain (CRD) which contains the DHHC 
(Asp-His-His-Cys) motif, and variable N- and C-termini (11). The C-terminus is after all TMDs and 
is generally considered to be directly after a highly conserved TTxE motif, which is found after the 
last TMD. In the zDHHC family, the C-termini widely vary in terms of sequence length, identity, 
and overall function. Several studies have identified variable, PAT-specific functional regions and 
motifs in the C-terminus, primarily affecting localization (80,81). A study by González Montoro et 
al. hinted that the C-terminus may have a conserved role in enzyme regulation (82). The study 
identified a sequence motif called the Palmitoyltransferase Conserved C-Terminus (PaCCT) motif 
in the C-terminus of zDHHC PATs, characterized by a NP[F/Y]xxGxxxxN consensus sequence. 
The aromatic residue within this motif is highly conserved and essential to Swf1 and Pfa3 
substrate palmitoylation. While this study did not elucidate a biochemical mechanism of C-
terminus function, the authors proposed a role in protein-protein interactions. Additionally, the 
PaCCT motif is not found in zDHHC1, 3, 4, 7, 11, 21, 22, and 23. This suggests that either the 
PaCCT motif is only responsible for regulation of a subset of PATs, or sequence alignments alone 
are not enough to understand the diversity and evolution of the C-terminus. 
 The objective of this study was to understand the role of the C-terminus in the regulation 
of PATs. Our experiments were guided by two assumptions: first, that PAT termini, like many 
other membrane proteins, are predicted to have intrinsically disordered regions (IDRs). Second, 
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based on the mounting evidence that disorder can have functional consequences, we assumed 
that the flexible and dynamic nature of these tails would play a role in regulating functions. In this 
study, we use computational tools to demonstrate that there is a region predicted to undergo a 
disorder-to-order transition that is conserved in most PATs, a subset of which contains the PaCCT 
motif. We propose ‘CCR’ (conserved C-terminal region) as an alternative nomenclature to more 
accurately describe the conserved region in the C-terminus. In the Ras PATs we show that the 
CCR is required for enzyme function. The CCR gains α-helical structure upon interaction with 
membrane mimetics, and we propose that this protein-membrane interaction is regulated by a 
conserved, phosphorylation-dependent electrostatic switch. Finally, we propose that in yeast, 
CCR-membrane interaction promotes association with an enzyme critical to fatty acid metabolism, 
Acc1, which appears to be a conserved mechanism of regulating substrate palmitoylation. This 
interaction may be conserved and serve as a mechanism of regulating substrate palmitoylation. 
4.2 Intrinsic Disorder in zDHHC PATs  
4.2.1 Predicted Regions of Intrinsic Disorder in PATs 
As a preliminary analysis, it is often useful to classify protein regions as ordered versus 
disordered. Human DHHC PATs were classified based on their N-terminal, C-terminal, and 
membrane-associated (entire PAT, excluding tails) regions (Fig. 4.1). As expected, all analyses 
showed that the membrane-associated regions of DHHC PATs are likely highly structured. Many 
N-termini were excluded, as they did not meet the minimum length cutoff value for CDF analysis. 
This observation indicated that most N-termini may not have major structural features. The rest 
of the N-terminal tails tend to be highly disordered by all analyses, with the exceptions of the 
ankyrin-repeat containing PATs (DHHC13, 16, 17). Conversely, most C-termini have a mixture of 
order and disorder. No correlation could be drawn between C-terminal length and likelihood of 
order vs. disorder, although our analysis must be expanded to evolutionary orthologues to 
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definitively conclude this. Interestingly, C-termini cluster in a distinct region in the CH plot, 
suggesting some level of conservation in terms of mean net charge and hydrophobicity. 
4.2.2 A Conserved C-Terminal Region (CCR) in PATs 
 PONDR VL-XT analysis of human zDHHC proteins revealed at least one highly ordered 
region in the C-terminus often surrounded by varying lengths of disordered residues, 
characterized by a sharp dip from disorder to order (Fig. 4.2A). Regions of disorder-to-order 
transition are often involved in molecular interactions and are referred to as molecular recognition 
features (MoRFs). It is interesting to note that the PaCCT motif found in several PATs is found 
Figure 4.1: Binary disorder analyses of human DHHC PATs. N-termini (red squares), C-termini (blue triangles), 
membrane-associated regions (black circles), and full length PATs (gold diamonds) were evaluated by (A) charge-
hydropathy, (B) cumulative distribution function, and (C) combined CH-CDF analysis. Mean net charge represents all 
charged residues besides histidine. Hydrophobicity was determined using the Kyte -Doolittle hydropathy scale (window 
= 5). CDF analysis was performed using PONDR VSL2 predictions.  
Guide:  
CDF (A): Above line = ordered, below line = 
disordered, crossing line = ambiguous 
CH (B): Left of line = disordered, right of line = 
ordered, within dashed lines = ambiguous 
CH-CDF (C):  
 Q1 (upper right): unusual (CH = 
disordered, CDF = ordered) 
 Q2 (upper left): disordered (both) 
 Q3 (lower left): mix (CH = ordered, 
CDF = disordered) 
 Q4 (lower right): ordered (both) 
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within these dips in the disorder plots, suggesting that the function of this motif may be associated 
with structure dependent interactions. 
 However, the PaCCT-containing MoRFs of several PATs (including 2, 6, 12, 13, 15, 17, 
and 20), extended far past the length of the PaCCT motif (defined as Nx[F/Y]xxGxxxxN), and this 
additional region was partially conserved with the single MoRF found in zDHHC3, zDHHC7, 
zDHHC21, and zDHHC22 (characterized by a VFG[x6]WxxP motif) (Fig. 4.2B). Therefore, we 
propose that these different motifs are evolutionarily related. To define the diversity of the 
conservation of this putative MoRF, we will hereafter address these regions as ‘conserved C-
terminal regions’ (CCR). Within the CCR, we propose that there are three primary subsets: the 
PaCCT-only subset, the VFG-only subset, and the combined PaCCT-VFG subset (Fig. 4.3). 
Generally, secondary structure predictors indicate that the PaCCT subset has propensity to form 
α-helical structures, while the VFG subset appears to be prone to β-sheet containing structures.  
 Figure 4.2: Presence of conserved C-terminal regions (CCRs) in mammalian zDHHC PATs. (A) Disorder 
predictions of a zDHHC PAT (human zDHHC7). Blue boxes represent termini (B) Truncated sequence alignment was 
created by extracting putative MoRFs containing PaCCT motifs from PONDR VL-XT predictions. Additonal MoRFs 
were added that did not contain PaCCT motifs, but contained homology to PaCCT-containing MoRFs. Colored boxes 
represent conserved sequence signatures. The WebLogo is a representative of all CCRs in mammalian PATs.  
A B 
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 As these observations are broad generalizations, several points should be noted. First, 
some PATs such as zDHHC14 and zDHHC8 have long C-terminal tails with several predicted 
MoRFs; however, these PATs only contain 1-2 regions with one of the motifs characteristic of a 
CCR. Also, while there is strong sequence similarity between CCRs within subsets, there are 
often subtle differences that could significantly modulate the structural characteristics of the 
region, such as differentially placed prolines or amino acid substitutions/deletions.  
4.2.3 Analysis of Ras PAT CCR Conservation 
Within zDHHC9 orthologues, the MoRF of the CCR was the only one found, and the CCR 
is highly conserved even in distantly related homologs such as S. cerevisiae Erf2. Ras PAT CCRs 
contain a PaCCT motif (Fig. 4.4), and previously it was identified that a well conserved aromatic 
residue in the PaCCT motif of Swf1 and Pfa3 were critical to PAT function. Therefore, we 
proposed that the aromatic residue in Ras PATs would be similarly critical to PAT function.  
Directly adjacent to the carboxy-end of the Erf2 PaCCT motif are two conserved prolines 
(Pro325 and Pro328 in Erf2), likely serving to restrict the length and helicity of the region. Adjacent 
to the carboxy-end of these prolines are two serines (Ser329 and Ser332), the first of which 
(Ser329) is highly conserved in all Ras PATs. The second (Ser332) is only found in fungal Ras 
PATs, and this switches to an aspartate in multicellular organisms, potentially representing an 
Figure 4.3: Subsets of CCRs containing conserved sequence signatures. Red indicates PATs containing VFG 
motifs, blue indicates PATs containing PaCCT motifs, and the intersection represents PATs containing both.  
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evolutionary-enacted phosphomimetic. Therefore, we hypothesized that at least one of these 
serines were phosphorylated in Erf2, and this would affect the function of the Erf2 CCR.  
 
 Hereafter, the CCR will refer to this region as a whole, PaCCT will refer to the MoRF 
predicted to form α-helices, and SxxD motif will refer to the conserved proximal serines that are 
potentially phosphorylated. 
4.2.4 The Ras PAT CCR is required for function 
PONDR VL-XT and PONDR-FIT algorithms were applied to the sequences of Erf2 and 
zDHHC9, in order to map potential functional regions (Fig. 4.5A). TM regions were mapped using 
the TMHMM predictor combined with previously performed Suc/SucT insertion experiments in 
Erf2, which demonstrate that the Erf2 CCR is not a transmembrane domain (Kayoko Ishizuka, 
unpublished data). Deletion of the CCR in zDHHC9 reduced or completely eliminated Ras PAT 
function as measured by our yeast genetic assay, which determines palmitoylation-dependent 
Ras2 function (Fig. 4.5B). Deletions of the C-terminus slightly altered protein levels (Fig. 4.5C) 
Figure 4.4: WebLogo sequence consensus representation of Erf2 and related CCRs throughout evolution.  The 
consensus is derived from human zDHHC9, zDHHC14, and zDHHC18, S. cerevisiae Erf2, C. intenstinalis zDHHC14 
(GI: 198427890), N. vectensis zDHHC9 (GI: 156377027), D. melanogaster zDHHC9 (GI: 281366130), S. purpuratis 
zDHHC14 (GI: 390334287), A. queenslandica zDHHC14 (GI: 340375495), S. mansoni zDHHC9 (GI: 256084522), and 
D. rerio zDHHC9 (GI: 158518002). The underlined regions represent either the MoRF containing the PaCCT motif 
predicted to fold into α-helices, or the proximal conserved SxxD motif. In the alignment of Erf2 and zDHHC9, the 
sequences displayed are 302-333 and 267-299, respectively. In the alignment, bold represents identical residues, 
green represents potentially phosphorylated serines, and the asterisk denotes the conserved aromatic residue that is 
important to function in the PaCCT motif (Tyr309 and Tyr274 in Erf2 and zDHHC9, respectively).  
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We also observe that mutation of the Erf2 and zDHHC9 tyrosine corresponding to the 
conserved residue in Swf1 and Pfa3 result in a loss of palmitoylation-dependent Ras2 function 
(Fig. 4.6). In the case of Erf2, elevated temperatures (35°C) and low-copy plasmids were required 
to see this loss-of-function phenotype, and increasing the expression via a high-copy plasmid was 
able to rescue the wild-type phenotype. Taken together, these results indicate that the effect of 
the Erf2 C-terminus on Ras2 palmitoylation is dependent on the level of expression. 
We hypothesized that this observed phenotypic difference is a result of protein-protein 
interaction. The possibility exists that the observed phenotypic difference is not a result of an 
interaction, but of a post-translational modification at the tyrosine residue. However, this is unlikely 
for multiple reasons. In the PaCCT motif, the aromatic residue is about evenly distributed between 
Figure 4.5: The Ras PAT CCR is Required for Function. (A) Domain structure of full-length zDHHC9 (1-364). (B) 
Complementation assay to assess the ability of ZDHHC9-GCP16 to suppress the loss of ERF2 in S. cerevisiae. Strain 
RJY1330 harboring pESC-TRP based plasmids were monitored for RAS2-independent growth. C169A is the 
catalytically inactive ‘DHHA’ mutation. ‘ΔallC’ (1-260) includes both ‘ΔCCR’ (Δ261-310) and ‘ΔVarC’ (1-310). Cells were 
plated at 1:10 dilutions starting from 4 x 107 cells/mL. (C) Steady-state levels of zDHHC9 deletions. All experiments 
were repeated at least 3 times. 
 
Figure 4.6: Conserved aromatic residue is important to Ras PAT function. (A) Assessing zDHHC9 Y274A using 
the previously discussed complementation assay. C169A is the catalytically inactive ‘DHHA’ mutant. (B) 
Complementation assay of Erf2 Y309A in two different vector backbones (low-copy pRS314, high-copy pESC-TRP). 
C203S is the catalytically inactive ‘DHHS’ mutant. Cells were plated at 1:10 dilutions starting from 4 x 107 cells/mL. 
Experiments were repeated at least 3 times.  
A 
B C 
A B 
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Phe and Tyr, implying that aromaticity is the functional feature. Additionally, tyrosine 
phosphorylation in S. cerevisiae is rare (214), and sulfation would require that the C-terminus to 
be localized to the lumen. Finally, multiple LC-MS/MS analyses of purified Erf2-Erf4 have not 
shown peptide mass shifts on the tyrosine characteristic of any modification.  
4.3 Structural Mechanism of the Erf2 CCR  
4.3.1 TFE and SDS Micelles Induce Helical Structure 
Our computational analyses hint at a structural role of the CCR. To determine the 
structural characteristics of the Erf2 CCR, we chemically synthesized and purified a 
representative peptide representing the PaCCT-containing MoRF. This peptide formed a random 
coil structure at pH 7.5 (20 mM SPB), and titration of a known helix-inducer 2,2,2-trifluoroethanol 
(TFE) (215,216) induced α-helical structure at an IC50 approximately 25% TFE (Fig. 4.7A, B). The 
isodichroic point at [θ]222 was estimated to be ~202.6 nm, characteristic of a two-state coil-to-helix 
transition (Fig. 4.7C).  
Figure 4.7: The Erf2 CCR undergoes a two-state coil-to-helix transition in the presence of TFE. (A) Far-UV CD 
of a peptide representing the Erf2 PaCCT-containing MoRF (sequence: NIYNKGSFLKNMGHLMLEPC) in 20 mM SPB 
pH 7.5 in the presence of varying TFE concentrations. (B) TFE vs. [θ]222 to determine LogIC50 and Hill Slope. (C) 
Determination of the isodichroic point through testing signal dependence on [θ]222.  
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To determine if folding could be induced by formation of detergent micelles, we added 
SDS at concentrations below and above the SDS critical micelle concentration, which is 
approximately 6-8 mM. At SDS concentrations below the CMC (0-1 mM), the peptide transitioned 
from a random coil to residual structure characteristic of a type II beta-turn (217). However, at 
concentrations above the CMC, the spectral characteristic of α-helical structure can be observed, 
indicating that the region likely forms helices in the presence of membranes, potentially 
suggesting interaction (Fig. 4.8A). The minima are less pronounced at higher SDS 
concentrations, which we hypothesize is due to SDS concentration-dependent changes in micelle 
curvature. Mapping the residues on a helical wheel indicates that the induced helix is likely to 
have amphipathicity, with a clearly distinguishable hydrophobic face and polar face (Fig. 4.8B). 
As the conserved tyrosine is present on the polar face, we propose that this residue may not be 
interacting with the membrane, but instead is exposed to water. More detailed structural analyses 
would be required to elucidate this possibility. 
 
 
 
Figure 4.8: The Erf2 CCR folds into α-helices in the presence of SDS micelles. (A) Far-UV circular dichroism of a 
purified peptide representing the Erf2 PaCCT-containing MoRF in the presence of varying SDS concentrations and 20 
mM SPB pH 7.5. The critical micelle concentration of SDS in the absence of salt is approximately 6 -8 mM. Spectra are 
representative of 3 accumulations. (B) Amphipathicity of the Erf2 and zDHHC9 helixes. Residues from Ile308-Pro325 
(Erf2) and Asn272-Pro290 (zDHHC9) were mapped on a helical wheel. Nonpolar residues are colored yellow, polar 
residues are colored green, basic residues are colored blue, and acidic residues are colored pink. Red circles represent 
the conserved aromatic residues within the PaCCT motif implicated in function.  
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4.3.2 The CCR is Required for Erf2 Phosphorylation 
Due to the level of conservation of serines proximal to the PaCCT motif within the Erf2 
CCR, we anticipated that at least one of these serines would be phosphorylated. Previous work 
in our laboratory using radioactive labeling demonstrated that Erf2 is phosphorylated in an Erf4-
dependent manner, which can also be observed as an increase in apparent molecular mass on 
an SDS-PAGE gel (Fig. 4.9A) (Lihong Zhao, unpublished work). Coincidentally, when checking 
Erf2 deletion mutants for expression (Fig. 4.9B), we noticed that deletion of the region 
encompassing the CCR not only reduced the relative amount of phospho-shifted Erf2, but also 
removed the Erf4-dependency (Fig. 4.9C). The Y309A mutant expression profile did not 
perceptibly differ from wild-type, further suggesting that the serines within the CCR were 
responsible for the mass shift. However, mutation of these residues still did not reduce the level 
of mass shift, indicating that more complex processes regulate Erf2 phosphorylation (Fig. 4.9D). 
In order to characterize the locations of Erf2 phosphorylation, we expressed and purified 
Erf2-Erf4 complexes essentially as previously described. To attempt to separate phosphorylated 
and non-phosphorylated species, we excised gel fragments representing the non-phosphorylated 
band (‘lower’) and the likely phosphorylated, mass-shifted band (‘upper’) (Fig. 4.10A). 
Furthermore, we treated this protein preparation with phosphatase, which reduced some but not 
Figure 4.9. The CCR affects Erf2 phosphorylation levels. (A) Erf4-dependent phosphorylation determined by 
autoradiography. (B) Domain structure of Erf2, starting with the DHHC-CRD. (C) Erf4-dependent expression of Erf2 
mutants and deletions. Deletion of the CCR results in reduction of the Erf2 mass-shift. (D) Mutation of serines within 
the CCR (3A: S313A, S329A, S332A) does not decrease the levels of mass-shifted Erf2.  
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all levels of the ‘upper’ band. After trypsin digestion and LC-MS/MS, we observed a number of 
peptide mass increases associated with phosphorylation in Erf2 (Fig. 4.10B, Table 4.1). One of 
the serines proximal to the CCR (S329) were modified, suggesting that phosphorylation may 
regulate the function of the CCR. In addition, four modifications were observed in the N-terminus 
(S11, S13, T14, S15), and two modifications at the extreme C-terminus (S348, S352). 
  
Figure 4.10: LC-MS/MS analysis of Erf2 reveals phosphorylated residues. (A) Purification of Erf2-Erf4 complexes 
results in three major species on a silver stained gel: GST-Erf4, Erf2 (upper band), and Erf2 (lower band). (B) Total 
number of phosphate modifications detected by mass spectrometry. Yellow highlight represents peptide coverage, and 
green highlights represent modified residues (‘p’: phosphorylation, ‘o’: oxidation). Red boxes represent TMDs , purple 
boxes represent DHHC-CRD, and green boxes represent the CCR. Figure generated by Scaffold 4 software. 
Table 4.1: Quantification of Erf2 Phosphorylation. Ascore measures the probability of correct phosphorylation site 
localization, where scores >20 are generally regarded as good. The number of detected spectral counts are separated 
based on which sample they were extracted from (upper band, lower band, phosphatase -treated lower band). 
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We also observed other types of modifications. Several instances of methionine oxidation 
were observed, although these are likely artifacts of the protein production process. We observed 
several acetylated lysines, mostly in the C-terminus both within and outside of the CCR (Table 
4.2). This is potentially interesting, as our group has previously shown that a subset of six residues 
in the C-terminus are ubiquitinated (83). While we did not observe any peptide mass shifts 
characteristic of ubiquitin modification (Gly-Gly), we assume that this may be due to the presence 
of Erf4, which has been shown to almost completely eliminate C-terminal ubiquitination. 
4.3.3 Dissection of Erf2 Phosphorylation 
Based on the spectral counts between the different types of Erf2 that were gel extracted, 
we expected that removal of S348 and S352 would be able to reduce Erf2 mass-shift while 
retaining phosphorylation dependence on Erf4 presence. We equally expected that mutation of 
most or all of observed phosphorylation residues would be required to completely eliminate Erf4-
dependent phosphorylation, mainly due to the promiscuity of phosphorylation, the size of the 
mass shift, and the general pitfall of amino acid mutation potentially shifting the equilibrium of 
modifications to different residues. To test this hypothesis, we designed mutations, deletions, and 
combinations of these in Erf2 based on the phosphorylation sites determined by mass 
spectrometry (Table 4.3).  
Table 4.3: Summary of Erf2 mutations and deletions to dissect Erf2 phosphorylation 
Table 4.2: Quantification of Erf2 acetylation. K188 falls within the DHHC-CRD, and the other four are found at the 
C-terminus. These C-terminal acetylated lysines are potentially also ubiquitinated.  
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We observed that in addition to deletion of residues including S348 and S352, at least 
deletion of the first 15 amino acids and mutation of S329 could eliminate gel-shifted Erf2 (Fig. 
4.11A). After further refinement, we found that only deletion of the first 15 residues was required 
to see this effect, contrary to our initial hypothesis (Fig. 4.11B). Furthermore, we could 
recapitulate this result with purified Erf2-Erf4 complexes (data not shown). 
Previously, our group has observed that with purified proteins, phosphatase-treatment of 
Erf2 does not affect autopalmitoylation or transfer to substrate (Lihong Zhao, unpublished data). 
To test the hypothesis that phosphorylation of Erf2 affects its physiological function, we tested 
several combinations of our mutations and deletions, most notably D1, which would remove the 
Erf2 mass-shift. No combination of mutants tested reduced Erf2 palmitoylation function (Fig. 
4.12). While this does not eliminate the possibility that phosphorylation somehow affects Erf2 
function in physiological conditions, we postulate that either phosphorylation works in tandem with 
another region of the protein to affect Erf2 function, replacement of residues with phosphomimetic 
residues would change function, or that the mass-shifted Erf2 behaves essentially the same as 
wild-type.  
Regardless, based on these observations, we decided to only pursue the potential 
functions of phospho-serines in the CCR, since these were conserved and therefore potentially 
important to function.  
Figure 4.11: Analysis of mutations and deletions implicated in Erf2 phosphorylation. Combinations of mutations 
and deletions were recombined into pESC-Leu/Erf4 vector, two transformants each were induced in minimal media 
plus galactose. All SDS-PAGE gels were 12%. Blank lanes represent unsuccessful transformants. (A) Testing all 
possible combinations with D2 demonstrated that at least D1 and 1A were also required to abolish doublet. (B) D1 is 
the only deletion required to abolish the doublet.  
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4.4 Function of the Erf2 CCR  
4.4.1 A Review of Previous Observations of the Erf2 C-Terminus 
While several experiments have addressed potential functions of the Erf2 C-terminus, no 
clear role has emerged. Here, I will review published and unpublished observations regarding the 
C-terminus to provide the conceptual foundation of subsequent studies. It appears that deletion 
of the C-terminus reduces steady-state autopalmitoylation and subsequent transfer Ras2, 
suggesting a potential role in catalysis (83). While this role is like that of the regulatory subunit 
Erf4, it has also previously been noted that removal of the Erf2 C-terminus does not affect 
interaction levels with Erf4 (83), and I have also observed this for zDHHC9-GCP16 (Fig. 4.13). 
However, based on our numerous observations of the Erf2 mass-shift (i.e. Erf4 and C-terminal 
dependence) and previous Erf2-Erf4 interaction mapping studies (Cheryl Budde, unpublished 
data), it is possible and perhaps likely that the Ras PAT C-terminus interacts with the regulatory 
subunit in some fashion. Further studies are required to explore this relationship. 
Contrary to previous results about zDHHC localization signals (80,81), we have previously 
observed that complete deletion of the C-terminus did not perceivably affect perinuclear staining 
of Erf2 (Kayoko Ishizuka, unpublished data). Instead, deletion of the N-terminus resulted in mis-
localization to the vacuole. As the region implicated in localization (25-45) was downstream of the 
Figure 4.12: Removal of phosphorylation sites implicated in Erf2 mass-shift do not affect Erf2 function. 
Complementation assay was performed essentially as previously described in Fig. 4.5 (strain RJY1330).  
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phosphorylated residues implicated in the Erf2 mass-shift, it is likely that Erf2 localization is not 
directly dependent of phosphorylation.  
Finally, previous work in the lab has demonstrated that treatment of purified Erf2-Erf4 
complexes with phosphatase does not influence enzyme activity (Lihong Zhao, unpublished data). 
Therefore, we propose that if phosphorylation of the Sxx[S/D] motif proximal to the PaCCT motif 
was important for function, it would do so in a more physiological setting. 
4.4.2 A Conserved Tyrosine Within the Erf2 CCR Does Not Affect Catalytic Activity 
Our initial expectation was that mutations of the CCR would affect some aspect of the 
catalytic mechanism, as deletion of the C-terminus reduces steady-state autopalmitoylation and 
subsequent transfer to Ras2 (83). However, experiments with purified protein revealed that the 
Y309A mutation did not affect either step of the palmitoylation reaction (Fig. 4.14). 
Figure 4.13: Co-immunoprecipitation of zDHHC9 and GCP16. FLAG-tagged zDHHC9 and myc-tagged GCP16 were 
expressed off of the GAL10 and GAL1 promoters, respectively, in RJY1330. ΔallC (1 -260) represents deletion of both 
CCR and VarC. 
Figure 4.14: Mutation of Erf2 Tyr309 does not affect autopalmitoylation or transfer to Ras2. In-gel 
autopalmitoylation and transfer reactions using BODIPY® C12:0-CoA as the acyl donor, run on a non-reducing SDS-
PAGE gel. Steady-state autopalmitoylation reactions were visualized using ex. 488 nm/em. 520 nm filters (Typhoon, 
GE Healthcare, Piscataway, NJ), and total purified Erf2 was determined by UV imaging of the SDS-PAGE gel on a 
ChemiDoc XRS+ imager (Bio-Rad). The amount of BODIPY® C12:0 transferred to Ras2 was determined by ex. 488 
nm/ em. 520 nm filters, and the total amount of Ras2 loaded was determined by mChe rry fluorescence. 
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4.4.3 The Erf2 CCR Regulates Several Potential Interactions 
To determine the function of the Erf2 CCR, we incorporated an N-terminal TAP tag into 
the full-length protein (218). Inclusion of this tag was able to complement the loss of Erf2 in our 
genetic assay, indicating that TAP-Erf2 was properly folded and localized (data not shown). To 
capture different proposed structural states, we utilized an empty vector control and three different 
Erf2 alleles: wild-type, Y309A (CCR mutant, proposed cytosolic-facing interactions), and 
S329A/S332A (2A; membrane-bound CCR interactions). We also utilized three different 
detergents (Triton X-100, C12E8, DDM)  previously optimized to determine the broadest possible 
interactome (219). A complete list of LC-MS/MS results is supplied below (Table 4.4).  
Table 4.4: List of Erf2 interactors, sorted from highest to least total spectral counts.  
List 1/4 vector WT Y309A S329A/S332A
Gene Name MW Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM
ERF2 41 kDa 0 3.9228 15.987 255.78 137.15 161.19 160.05 149.39 149.39 138.72 77.684 103.79
TEF1 50 kDa 300.82 382.48 482.79 57.798 154.29 170.62 26.997 154.16 154.16 98.736 19.122 114.11
SSA1 70 kDa 214.05 176.53 102.31 113.14 138.1 133.76 92.56 139.85 139.85 79.152 155.37 128.79
SHR5 (ERF4) 27 kDa 0 11.768 15.987 120.51 100.01 85.741 104.13 91.382 91.382 122.4 94.416 104.88
TDH3 36 kDa 254.54 156.91 207.83 49.189 83.814 54.874 43.066 50.856 50.856 38.352 2.3903 24.453
PMA1 100 kDa 11.57 0 0 76.244 55.241 45.443 68.135 44.499 44.499 44.064 89.635 33.691
RPS18A 17 kDa 0 13.73 22.381 49.189 34.288 46.3 52.065 46.883 46.883 70.992 83.66 51.623
SSB2 67 kDa 133.06 149.07 38.368 41.811 68.575 54.874 19.283 42.91 42.91 17.136 60.952 39.668
RPL12A 18 kDa 133.06 72.572 137.48 38.122 27.621 43.728 26.354 39.731 39.731 39.168 47.805 26.627
PET9 34 kDa 144.63 33.344 6.3946 60.257 41.907 3.4296 43.709 5.5624 5.5624 60.384 5.9757 4.8906
RPS27B 9 kDa 52.065 45.112 63.946 22.135 18.096 23.15 19.926 37.348 37.348 27.744 25.098 24.453
ATP1 59 kDa 0 0 70.341 13.527 15.239 21.435 27.64 31.785 31.785 31.824 0 32.061
NAP1 48 kDa 0 0 0 0 0 77.167 0 24.633 24.633 0 0 65.208
RPS14B 15 kDa 0 3.9228 12.789 24.595 12.382 17.148 27.64 16.687 16.687 26.112 50.196 19.019
PHO84 64 kDa 0 0 0 22.135 37.145 18.006 23.783 15.098 15.098 34.272 32.269 14.128
RPS20 14 kDa 0 21.576 35.17 18.446 15.239 16.291 17.355 20.66 20.66 20.4 35.854 16.302
ACC1 250 kDa 0 0 0 0 0 3.4296 3.2139 1.5893 1.5893 37.536 88.44 41.299
URA2 245 kDa 0 0 0 11.068 7.6195 8.5741 8.3561 7.9463 7.9463 29.376 57.367 28.8
ARF1 21 kDa 0 15.691 38.368 0 11.429 18.863 12.213 19.071 19.071 12.24 23.903 16.302
ACT1 42 kDa 63.635 9.8071 0 36.892 25.716 27.437 7.7134 11.919 11.919 10.608 2.3903 10.868
HSC82 81 kDa 0 0 0 14.757 16.191 19.72 15.427 12.714 12.714 12.24 27.488 14.672
RPP2A 11 kDa 0 0 0 17.216 17.144 16.291 9.6417 16.687 16.687 16.32 17.927 11.955
CDC19 55 kDa 0 0 44.762 0 5.7146 24.865 0 18.276 18.276 4.896 2.3903 26.083
RPS10A 13 kDa 0 0 0 13.527 6.667 12.861 14.141 12.714 12.714 19.584 17.927 12.498
KAR2 74 kDa 0 64.727 31.973 14.757 16.191 17.148 5.785 18.276 18.276 8.16 19.122 20.649
RPP0 34 kDa 0 0 0 27.054 14.287 14.576 12.856 14.303 14.303 16.32 0 7.0642
SSC1 71 kDa 0 60.804 0 2.4595 22.858 2.5722 1.9283 3.1785 3.1785 4.896 47.805 10.325
HXT6 63 kDa 0 0 0 8.6081 20.001 4.2871 14.784 11.125 11.125 12.24 19.122 8.6944
LEU2 39 kDa 0 0 0 3.6892 3.8097 1.7148 10.927 13.509 13.509 19.584 0 16.302
RPS0A 28 kDa 0 5.8842 0 11.068 11.429 6.8593 7.0706 9.5355 9.5355 16.32 13.147 7.6076
SSA2 69 kDa 0 147.11 0 89.771 114.29 110.61 73.277 111.25 111.25 62.016 133.86 104.88
ENO1 47 kDa 0 19.614 54.354 0 19.049 7.7167 0 11.919 11.919 0 0 11.411
ATP2 55 kDa 57.85 3.9228 0 11.068 7.6195 0 25.711 2.3839 2.3839 17.952 0 4.8906
VMA2 58 kDa 0 0 0 9.8379 12.382 0 13.498 9.5355 9.5355 12.24 3.5854 13.042
RPS16A 16 kDa 0 0 0 8.6081 0 1.7148 19.926 9.5355 9.5355 8.16 9.5611 8.151
RPL40A 15 kDa 0 0 0 29.514 19.049 6.8593 0 2.3839 2.3839 9.792 0 5.9774
FKS1 215 kDa 0 0 0 3.6892 12.382 4.2871 10.284 4.7678 4.7678 8.976 16.732 7.6076
MIR1 33 kDa 0 0 0 4.9189 5.7146 0 19.926 0 0 27.744 2.3903 2.717
PDR5 170 kDa 0 0 0 7.3784 7.6195 12.004 6.4278 3.9731 3.9731 4.896 17.927 8.6944
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Table 4.4 (continued) 
List 2/4 vector WT Y309A S329A/S332A
Gene Name MW Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM
RPS28A 8 kDa 0 0 28.776 4.9189 0 9.4315 3.8567 11.125 11.125 6.528 0 8.6944
RPS19A 16 kDa 0 11.768 0 8.6081 7.6195 2.5722 5.785 4.7678 4.7678 8.976 8.366 5.9774
ENA1 120 kDa 0 0 0 6.1487 0 3.4296 10.284 0 0 7.344 17.927 13.042
RPL22A 14 kDa 0 11.768 0 0 2.8573 4.2871 7.7134 7.9463 7.9463 10.608 8.366 3.2604
RPS24A 15 kDa 0 0 0 0 2.8573 6.0019 10.284 7.1517 7.1517 8.16 9.5611 7.0642
RPS26A 14 kDa 0 0 0 0 0 0 5.785 0 0 7.344 0 0
RPS5 25 kDa 0 0 0 7.3784 3.8097 0 1.9283 4.7678 4.7678 7.344 13.147 9.7812
RPL26B 14 kDa 0 0 12.789 3.6892 1.9049 5.1445 6.4278 9.5355 9.5355 3.264 3.5854 4.3472
RPS3 27 kDa 0 0 0 0 7.6195 0 10.927 2.3839 2.3839 17.136 0 4.3472
FBA1 40 kDa 0 0 0 19.676 17.144 12.861 0 2.3839 2.3839 0 0 0
ATP3 34 kDa 98.345 13.73 0 9.8379 9.5243 0 8.3561 0 0 6.528 0 0
HSP60 61 kDa 0 0 0 0 0 7.7167 3.2139 10.33 10.33 0 0 10.325
RPP2B 11 kDa 0 0 0 0 0 7.7167 4.4995 10.33 10.33 0 0 6.5208
RPL23A 14 kDa 0 0 0 2.4595 0 6.8593 8.9989 3.1785 3.1785 11.424 0 3.8038
RPS7A 22 kDa 0 0 0 2.4595 1.9049 5.1445 8.3561 3.9731 3.9731 6.528 3.5854 4.3472
TIM11 11 kDa 0 5.8842 0 0 4.7622 0 4.4995 2.3839 2.3839 6.528 13.147 3.2604
RPL11A 20 kDa 0 0 0 0 3.8097 5.1445 5.1422 4.7678 4.7678 4.896 0 3.2604
RPL28 17 kDa 0 0 0 0 0 4.2871 4.4995 8.7409 8.7409 0 0 7.6076
COX9 7 kDa 0 0 0 0 0 0 0 7.9463 7.9463 0 0 0
NDE1 63 kDa 0 0 0 0 5.7146 12.861 4.4995 1.5893 1.5893 1.632 0 6.5208
RPS12 15 kDa 0 0 0 0 0 0 12.213 0 0 15.504 4.7805 0
LAT1 52 kDa 11.57 3.9228 0 0 1.9049 0 5.785 7.1517 7.1517 0 0 3.2604
SSE1 77 kDa 11.57 0 0 2.4595 1.9049 6.8593 0 3.9731 3.9731 0 3.5854 7.6076
CHC1 187 kDa 0 0 0 0 0 1.7148 0 0 0 5.712 16.732 6.5208
MIC10 10 kDa 0 0 0 0 1.9049 0 0 0 0 0 4.7805 0
ADE5,7 86 kDa 0 0 0 0 0 0 12.213 0 0 4.896 11.951 0
NOP58 57 kDa 0 0 9.5919 3.6892 4.7622 3.4296 0 1.5893 1.5893 1.632 3.5854 3.2604
RPS13 17 kDa 0 0 0 6.1487 0 5.1445 5.1422 2.3839 2.3839 1.632 0 2.717
ILV5 44 kDa 0 0 0 6.1487 11.429 1.7148 5.1422 2.3839 2.3839 0 0 0
RPL43A 10 kDa 0 0 0 0 0 0 5.1422 6.357 6.357 2.448 0 1.6302
QCR2 40 kDa 0 0 0 0 2.8573 1.7148 1.2856 4.7678 4.7678 1.632 0 4.8906
TEF4 47 kDa 0 0 0 7.3784 7.6195 4.2871 3.8567 1.5893 1.5893 0 0 0
RPT1 52 kDa 0 0 0 2.4595 0 0 4.4995 4.7678 4.7678 4.896 0 1.6302
RPL10 25 kDa 0 0 0 0 0 0 3.2139 0 0 3.264 0 0
CLU1 145 kDa 0 0 0 0 0 0 0 8.7409 8.7409 0 0 4.3472
GAL2 64 kDa 0 0 0 0 0 0 7.7134 0 0 4.896 4.7805 3.2604
ENO2 47 kDa 0 17.653 41.565 0 20.001 5.1445 0 9.5355 9.5355 0 0 11.955
RPP1B 11 kDa 0 0 0 6.1487 0 4.2871 0 0 0 4.08 0 3.8038
YEF3 116 kDa 0 0 0 9.8379 3.8097 3.4296 5.1422 0 0 0 0 0
RPS25A 12 kDa 0 0 0 0 0 0 4.4995 3.9731 3.9731 0 0 0
RPL20A 20 kDa 0 0 0 2.4595 0 0 7.7134 3.1785 3.1785 0 0 0
HHT1 15 kDa 0 0 0 0 0 0 0 0 0 0 0 3.2604
RPL14A 15 kDa 0 0 0 7.3784 3.8097 0 4.4995 0 0 0 0 1.0868
FAA1 78 kDa 0 0 0 0 0 0 10.284 0 0 3.264 0 1.0868
PIL1 38 kDa 0 0 6.3946 0 0 1.7148 0 3.9731 3.9731 0 0 5.434
RPL27A 16 kDa 0 0 0 0 0 0 5.1422 3.9731 3.9731 0 0 0
RPS21B 10 kDa 0 0 0 0 0 2.5722 2.5711 2.3839 2.3839 2.448 0 2.1736
VMA1 119 kDa 0 0 0 0 0 0 7.0706 1.5893 1.5893 4.08 0 0
ERG28 17 kDa 0 0 0 4.9189 0 0 4.4995 0 0 4.896 0 0
TUB1 50 kDa 0 0 0 0 0 0 5.785 0 0 6.528 0 0
RPS9B 22 kDa 0 0 0 4.9189 0 0 9.6417 0 0 0 0 0
FAS1 229 kDa 0 0 0 0 0 2.5722 2.5711 1.5893 1.5893 0 3.5854 3.2604
RPL30 11 kDa 0 0 0 0 0 0 3.8567 3.1785 3.1785 1.632 0 1.0868
ERG20 40 kDa 0 0 0 6.1487 2.8573 2.5722 4.4995 0 0 0 0 0
ECM33 44 kDa 0 0 0 0 0 0 1.2856 0 0 3.264 8.366 0
RPL25 16 kDa 0 0 0 0 0 0 7.0706 0 0 2.448 0 0
FAS2 207 kDa 0 0 0 0 0 2.5722 1.2856 2.3839 2.3839 1.632 3.5854 2.717
YHM2 34 kDa 0 3.9228 0 4.9189 0 0 4.4995 0 0 4.08 0 1.0868
RPL38 9 kDa 0 0 0 0 0 1.7148 3.2139 3.1785 3.1785 2.448 0 0
RPS22A 15 kDa 0 0 0 0 0 0 4.4995 0 0 0 0 0
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Table 4.4 (continued) 
List 3/4 vector WT Y309A S329A/S332A
Gene Name MW Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM
SCP160 135 kDa 0 0 0 0 0 3.4296 1.2856 2.3839 2.3839 1.632 0 3.2604
COX6 17 kDa 0 0 0 0 0 1.7148 0 4.7678 4.7678 0 0 2.1736
RPS1B 29 kDa 0 0 0 0 0 0 6.4278 2.3839 2.3839 2.448 0 0
ITR1 64 kDa 0 0 0 0 0 0 0 0 0 4.896 0 0
OM45 45 kDa 0 0 0 0 2.8573 1.7148 1.9283 1.5893 1.5893 0 0 1.6302
GCN1 297 kDa 0 0 0 0 0 0 2.5711 0 0 5.712 2.3903 2.717
RPL31A 13 kDa 0 0 0 0 0 0 4.4995 0 0 0 4.7805 0
RPL13A 23 kDa 0 5.8842 0 0 0 0 0 3.1785 3.1785 0 0 1.6302
PDC1 61 kDa 0 0 0 0 10.477 2.5722 0 0 0 0 0 1.0868
PDA1 46 kDa 0 0 0 0 0 0 0 5.5624 5.5624 0 0 2.717
HTB1 14 kDa 0 0 0 0 0 0 0 2.3839 2.3839 0 0 1.6302
POR1 30 kDa 0 0 0 0 7.6195 0 1.2856 1.5893 1.5893 0 0 2.1736
GPH1 103 kDa 0 0 0 0 0 3.4296 0 0 0 0 0 5.434
AAP1 98 kDa 0 0 0 0 0 0 6.4278 0 0 0 8.366 0
PRM5 35 kDa 0 0 0 0 0 1.7148 1.9283 0 0 0 5.9757 1.6302
CCT8 62 kDa 0 0 0 0 0 1.7148 3.2139 0 0 4.08 0 0
PFK1 108 kDa 0 0 0 0 3.8097 6.8593 0 0 0 0 0 0
RPL18A 21 kDa 0 0 0 0 0 2.5722 0 0 0 0 0 5.434
HXK1 54 kDa 0 0 0 3.6892 11.429 0 0 0 0 0 0 0
YMR315W 38 kDa 0 0 0 0 0 1.7148 0 3.1785 3.1785 0 0 1.6302
GAL1 58 kDa 0 0 0 0 0 0 1.9283 2.3839 2.3839 0 0 3.8038
RPL4A 39 kDa 0 0 0 0 0 0 5.1422 2.3839 2.3839 0 0 1.0868
VTC4 83 kDa 0 0 0 2.4595 0 3.4296 2.5711 0 0 0 0 0
PSA1 40 kDa 0 0 0 0 0 0 0 0 0 1.632 0 5.9774
SEC27 99 kDa 0 0 0 0 0 0 3.2139 0 0 3.264 2.3903 1.6302
RNR2 46 kDa 0 0 0 0 0 0 0 0 0 5.712 0 0
PYC1 130 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
HHF1 11 kDa 0 0 0 0 0 0 4.4995 0 0 0 0 0
SAM1 42 kDa 0 0 0 0 0 0 0 0 0 0 0 4.3472
TY1A-A 49 kDa 0 0 0 0 0 1.7148 0 2.3839 2.3839 0 0 0
VTC1 14 kDa 0 0 0 0 0 1.7148 0 0 0 0 4.7805 0
RPN11 34 kDa 0 0 0 0 0 0 0 3.9731 3.9731 0 0 1.0868
COX13 15 kDa 0 0 0 0 0 0 0 4.7678 4.7678 0 0 0
PFK2 105 kDa 0 0 0 2.4595 0 2.5722 0 1.5893 1.5893 0 0 1.0868
BGL2 34 kDa 0 0 0 0 0 0 0 0 0 1.632 0 0
NOP56 57 kDa 0 0 0 0 0 1.7148 1.9283 0 0 0 0 1.6302
NIP1 93 kDa 0 0 0 0 0 0 1.2856 0 0 0 2.3903 2.717
PHO89 63 kDa 0 0 0 0 0 0 2.5711 1.5893 1.5893 0 0 1.0868
RPL3 44 kDa 0 0 0 0 0 0 2.5711 1.5893 1.5893 0 0 0
RPP1A 11 kDa 0 0 0 2.4595 0 0 1.9283 0 0 1.632 0 0
AAC1 34 kDa 0 0 0 0 0 0 0 0 0 7.344 0 0
RPL17A 21 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
THS1 85 kDa 0 0 0 0 0 4.2871 0 0 0 0 0 1.6302
TUB2 51 kDa 0 0 0 0 0 0 1.9283 0 0 5.712 0 0
RPS11A 18 kDa 0 0 0 0 0 0 3.8567 0 0 0 0 0
ERG3 43 kDa 0 0 0 0 0 0 0 0 0 1.632 0 2.1736
GRX2 16 kDa 0 0 0 0 0 0 1.9283 0 0 0 3.5854 0
CHO2 101 kDa 0 0 0 0 0 0 1.9283 0 0 1.632 0 1.0868
RHO1 23 kDa 0 0 6.3946 0 0 0 1.2856 0 0 0 0 0
TDH2 36 kDa 0 0 0 0 0 0 38.567 0 0 0 0 0
RPS17A 16 kDa 0 0 0 0 0 0 2.5711 0 0 1.632 0 0
DUG1 53 kDa 0 0 0 0 0 0 0 3.9731 3.9731 0 0 0
RPL33A 12 kDa 0 0 0 0 0 0 3.8567 0 0 0 0 0
KAP123 123 kDa 0 0 0 0 0 0 5.785 0 0 0 0 0
SUR1 45 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
VTC3 97 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
SNQ2 169 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 1.0868
LCB4 70 kDa 0 0 0 0 0 1.7148 0 0 0 0 0 1.0868
NDI1 57 kDa 0 0 0 0 0 0 1.2856 0 0 3.264 0 0
HSP104 102 kDa 0 0 0 0 0 0 0 0 0 0 0 3.2604
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Table 4.4 (continued) 
 
List 4/4 vector WT Y309A S329A/S332A
Gene Name MW Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM Triton C12E8 DDM
ILV2 75 kDa 0 0 0 0 0 0 0 0 0 0 0 2.717
RPL16B 22 kDa 0 0 0 0 0 0 3.2139 0 0 0 0 0
IDH2 40 kDa 0 0 0 0 0 0 0 0 0 0 0 3.8038
SSA4 70 kDa 0 0 0 40.581 0 0 0 0 0 0 0 0
YOP1 20 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 1.0868
RPN2 104 kDa 0 0 0 0 0 0 0 0 0 0 2.3903 1.0868
ALD6 54 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
RPL21A 18 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 1.0868
RET2 61 kDa 0 0 0 0 0 0 0 0 0 1.632 0 0
GLK1 55 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
SEC7 227 kDa 0 0 0 0 0 0 0 0 0 1.632 2.3903 0
KGD2 50 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
CDC42 21 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
ATP4 27 kDa 0 0 0 0 0 0 0 0 0 1.632 0 0
BMH2 31 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
RPL6A 20 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
PHO88 21 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
GAL10 78 kDa 0 0 0 0 0 1.7148 1.2856 0 0 0 0 0
PRC1 60 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
SEC26 109 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
RPL36A 11 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
YDJ1 45 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
SDH1 70 kDa 0 0 0 0 0 0 0 0 0 0 0 2.1736
ALD4 57 kDa 0 0 0 0 0 0 0 0 0 0 0 2.1736
RPS2 27 kDa 0 0 0 0 0 0 2.5711 0 0 0 0 0
SRP1 60 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
VTC2 95 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
DBP3 59 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
STT3 82 kDa 0 0 0 0 0 0 0 1.5893 1.5893 0 0 0
YPT1 23 kDa 0 0 0 2.4595 0 0 1.2856 0 0 0 0 0
BBC1 128 kDa 0 0 0 0 0 0 1.2856 0 0 1.632 0 0
CPA2 124 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
PMR1 105 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
KAP95 95 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
SDH2 30 kDa 0 9.8071 0 0 0 0 0 0 0 0 0 0
KGD1 114 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
VPH1 96 kDa 0 0 0 0 0 0 1.2856 0 0 0 2.3903 0
CCC1 34 kDa 0 0 0 0 0 0 0 0 0 1.632 0 0
RPS4A 29 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
PAB1 64 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
RPL9A 22 kDa 0 0 0 3.6892 0 0 0 0 0 0 0 0
RPG1 110 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
RVB1 50 kDa 0 0 0 0 1.9049 0 0 0 0 0 0 0
MAE1 74 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
PGM1 63 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
YGP1 37 kDa 0 0 0 0 0 0 0 0 0 1.632 0 0
RNA1 46 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
CDC48 92 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
CRM1 124 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
SNL1 18 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
RPN1 109 kDa 0 0 0 0 0 0 1.9283 0 0 0 0 0
STM1 30 kDa 0 0 0 0 0 0 0 0 0 0 0 1.6302
RAS2 35 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
CSM1 22 kDa 0 3.9228 0 0 0 0 0 0 0 0 0 0
CCT5 62 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
CPR6 42 kDa 0 0 0 0 0 0 0 0 0 0 0 1.0868
RPL2A 27 kDa 0 0 0 0 0 0 1.2856 0 0 0 0 0
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4.4.4 The Erf2 CCR Mediates a Functional Interaction With Acc1 
Our proteomic results suggested that acetyl-CoA carboxylase 1 (Acc1) would be a primary 
interaction of interest because of: high spectral counts compared to our positive control Erf4, it 
was a mutation-dependent interaction (being primarily found in the 2A mutant and not vector, wild-
type, or Y309A), and the interaction was preserved in all detergents used (Fig. 15).  
Acc1 is responsible for conversion of acetyl-CoA to malonyl-CoA, which is the rate-limiting 
step of de novo fatty acid synthesis (220) (Fig. 4.16A). Therefore, we hypothesized that this 
interaction may be a mechanism of controlling substrate palmitoylation. In co-immunoprecipitation 
experiments, we observed that Erf2 point mutants had similar interaction levels, while deletion of 
the C-terminus eliminated most observable interaction (Fig. 4.16B). We attribute this result to the 
different conditions and much higher stringency of the TAP experiment compared to the co-
immunoprecipitation experiment, combined with our model that the C-terminal mechanism is 
highly dynamic. 
Figure 4.15: Comparison of spectral counts between Erf4 (Shr5) and Acc1. Values taken from Table 4.4.  
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To evaluate if the function of Tyr309 could be associated with Acc1, we incorporated high-
copy Erf2 expression plasmids in RJY1277 and RJY1945. These strains have the same genotype, 
except that in RJY1945, ACC1 expression is reduced by means of a DAmP (Decreased 
Abundance by mRNA Perturbation) allele, which generally reduces expression ranging from four- 
to ten-fold (221). At elevated temperatures, the 2A/Y309A mutant but not the wild-type or the 2A 
mutant is sensitive to the loss of Acc1 expression (Fig. 4.17). This suggests that the Erf2-Acc1 
functionally interact through Tyr309, and this is able to conditionally modulate Ras2 
palmitoylation.  
 
Figure 4.17: Functional association between the conserved aromatic mutant and Acc1. Previously described 
complementation assay in either RJY1277 (containing wild-type ACC1) or RJY1945 (containing acc1-DAmP).  
Figure 4.16: Acetyl-CoA Carboxylase as a potential interacting protein with Erf2. (A) Fatty acid synthesis 
pathways in yeast. (B) Co-immunoprecipitation with FLAG-Erf2 mutants/deletions and Acc1-TAP (containing a CBP 
tag). ‘ΔBC’ is deletion of the entire C-terminus (1-301). ‘EV’ is empty vector. 
A B 
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4.5 Discussion 
While we are rapidly gaining understanding of the regulation of palmitoylated substrates, 
relatively few studies have focused on biochemical regulatory mechanisms of palmitoylation 
enzymes. It appears that at least subsets of this family of enzymes can be regulated by at least 
one of the following: subunits, oligomerization, zinc binding, or PTMs (57,83,89,90,92-95). Limited 
studies have been performed on the C-terminus, and it has been hypothesized that this is an 
additional mode of conserved regulation; however, no biochemical mechanism has been 
attributed to their function. In this study, we re-examined the C-termini of the PAT family using 
intrinsic disorder predictors, working under the assumption that using these tools would reveal 
functional features. Like many other membrane proteins, most PATs appeared to have at least 
one putative MoRF in the C-terminus. While certain PATs such as zDHHC14 had many putative 
MoRFs, one of these in particular (CCR) had conserved sequence signatures across most of the 
PAT family including the PaCCT motif, suggesting a partially conserved mechanism of action. 
The length and sequence signatures of conserved PAT MoRFs can be broadly categorized into 
three groups, where one of the groups has elements of the other two groups.  
Due to our knowledge of Erf2-Erf4, we used it as a model to understand the function of 
the PaCCT motif-containing CCR in Ras PATs, and potentially the C-terminus in general. We 
found that the CCR was able to undergo induced folding in the presence of membrane mimetics. 
The proximity of conserved, phosphorylated residue(s) is consistent with an electrostatic switch 
mechanism of membrane binding (Fig. 4.18). Further studies are required to definitively show not 
only that the Erf2 CCR can interact with membranes in more physiological contexts, but also if 
phosphorylation of one or both serines proximal to the CCR confers sufficient electrostatic 
repulsion to overcome the proposed hydrophobic association between the amphipathic helix and 
the lipid bilayer. Interestingly, in Ras PATs of complex multicellular organisms, the second serine 
is replaced with aspartate (S332D in Erf2), which we propose acts as a phosphomimetic residue. 
In this case, if the switch is still primarily phosphorylation-driven, only one phosphorylation event 
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may be required to initiate the electrostatic switch. Alternatively, this evolutionary change may be 
associated with a different membrane-binding switch mechanism, such as palmitoylation.  
In mammalian Ras PATs including zDHHC9, three cysteines are found within the CCR, 
and one of these are found on the hydrophobic face of the proposed helix. Palmitoylation of these 
cysteines could serve to anchor the helix to the membrane bilayer, directly participate in protein-
protein interactions, and/or other serve other mechanisms. At least one of the three cysteines of 
zDHHC9 (Cys288) is likely palmitoylated due to homology with known palmitoylated residues in 
related PATs zDHHC5 and zDHHC8 (88). Furthermore, we observe that endogenous zDHHC9 
is highly palmitoylated in rat brain (see Chapter 5). In the two non-mutually exclusive mechanisms 
of helical membrane-binding regulation, the reversible post-translational modification would either 
prevent/destabilize (phosphorylation) or initiate/stabilize (palmitoylation) coupled folding and 
binding with the membrane. However, not all PATs appear to have conserved residues for PTMs 
either within or proximal to the CCR, suggesting that some PATs may have C-termini that are 
constitutively bound or unbound to the membrane.  
Deletion of the Erf2 C-terminus had been previously noted to increase hydrolysis of the 
autopalmitoylation intermediate, and therefore decrease steady-state autopalmitoylation and 
subsequent transfer to Ras2 (83). Contrary to our initial expectation, mutation of the conserved 
aromatic residue or removal of phosphates did not affect either of these steps. This could be a 
reflection of the amphipathicity of the CCR, where each helix face may have a different function 
Figure 4.18: Model of membrane-binding regulation by phosphorylation. In this model, the C-terminus of native 
Erf2 binds to the membrane bilayer. Upon phosphorylation, electrostatic forces shift the equilibrium of the C -terminus 
to the unbound state. 
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in Erf2. While it is possible that the conserved tyrosine in the Erf2 CCR is embedded in the 
membrane, our helical wheel representation suggests a scenario where the polar face containing 
the aromatic residue would be responsible for interactions in the cytosol, whereas the hydrophobic 
face is embedded in the membrane and may be responsible for catalytic function. It is difficult to 
envision if/what the additional function(s) of the hydrophobic face would be without detailed 
biochemical and/or structural analyses. Potentially, it may serve to stabilize active site residues, 
or serve as a gate to protect the active site from water. Alternatively, it may interact with another 
protein embedded in the bilayer required for enzyme activity, such as Erf4.  
Our results suggest that the C-terminus coordinates an interaction with Acc1, a multi-
domain enzyme that converts acetyl-CoA to malonyl-CoA (220). As Acc1 has been previously 
demonstrated to be bound to the peripheral ER membrane, our model is that dephosphorylated 
Erf2 primarily binds Acc1 (222). Though a previous study has made an association with Acc1 and 
protein palmitoylation (223), this is to our knowledge the first known association between a PAT 
and an enzyme involved in fatty acid metabolism. While it has not been identified in 
palmitoylproteomic studies, it remains to be seen if Acc1 itself is palmitoylated, which would 
implicate the Ras PAT CCR in substrate recognition. Due to the conservation of CCRs in zDHHC 
PATs, we presume that this interaction may be relevant for the family of Ras PATs, if not other 
PATs containing PaCCT motifs. The disordered nature of MoRFs makes it likely that the 
membrane-bound CCR may coordinate other regulatory interactions in other conditions; however, 
we propose that Acc1 is the primary partner. It is also possible that the non-membrane bound 
CCR (i.e. phosphorylated Erf2) could coordinate a different set of potentially regulatory 
interactions, or even promote/deplete turnover, which is another known function of the C-terminus 
(83). Interestingly, the MoRF gains type II β-turn structure when exposed to free detergent 
molecules, which may serve as a mechanism of driving non-membrane bound interactions. The 
only interaction of note not found in phospho-deficient Erf2 (2A) but found in other Erf2 mutants 
was the heat-shock protein Ssa4, although this was only detected in Triton-solubilized extracts.  
76 
 
 We demonstrate that mutation of the conserved aromatic residue in Erf2 is sensitive to 
changes in Acc1 expression, suggesting that the Erf2-Acc1 interaction is critical for substrate 
palmitoylation. We propose two non-mutually exclusive scenarios of Acc1-dependent Erf2 
regulation, either of which would ultimately increase or maintain local acyl-CoA levels. Potentially, 
increasing the proximity of Erf2 to Acc1 could serve to spatially orient the de novo fatty acid 
synthesis pathway closer to the Erf2 (Fig. 4.19A). An alternative would be that Erf2-Acc1 
interaction results in increased local levels of malonyl-CoA, which could inhibit nearby carnitine 
palmitoyltransferases (CPT) bound to mitochondrial outer membranes (224), preventing import of 
acyl-CoA and subsequent β-oxidation (Fig. 4.19B). Regardless of the mechanism, this proposed 
link between fatty acid metabolism and protein palmitoylation may represent a conserved 
regulatory mechanism of protein palmitoyltransferases.  
Figure 4.19: Models of functional Erf2-Acc1 interaction. (A) Erf2-Acc1 links palmitoylation to de novo fatty acid 
synthesis, increasing local acyl-CoA levels. (B) Malonyl-CoA production inhibits nearby carnitine acyltransferases, 
decreasing acyl-CoA β-oxidation. 
A 
B 
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Similar previous observations regarding the C-terminus of Swf1 and Pfa3 demonstrate 
that this region somehow regulates substrate palmitoylation (82). In particular, the Pfa3 C-
terminus (and PaCCT motif) appears to regulate its localization to the vacuole, and the 
compatibility of this result with our model is not immediately obvious. If the Pfa3 C-terminus also 
regulates Acc1 interaction, one scenario is that this interaction would upregulate either 
palmitoylation of Pfa3 itself or a substrate responsible for its proper localization. Alternatively, the 
CCR of Pfa3 (and CCRs in general) may coordinate multivalent interactions or even modulate a 
different set of context-dependent interactions, which is a fundamental characteristic of disordered 
regions. These possibilities would be supported by the observation that the CCR is extended and 
has different sequence characteristics compared to Erf2. Future studies of PAT C-termini in the 
context of MoRFs will help understand the potential diversity of regulation.  
4.6 Experimental Procedures 
Cumulative distribution function (CDF). CDF is a binary analysis based on per-residue local 
sequence predictions (225). PONDR VSL2 (206) scores were used because of this predictor’s 
relative accuracy in CDF analysis. Disorder scores were be plotted against their cumulative 
frequency, and the resulting distributions were classified based on the distance from a previously 
validated linear boundary.  
Charge-hydropathy (CH) analysis. One established binary method of order-disorder classification 
is the CH plot, where ordered and disordered proteins plotted in charge-hydropathy space can be 
separated by a linear boundary (109). Absolute mean net charge for each region were determined 
by calculating the total amount of charged amino acids (Lys, Arg, Asp, Glu), then dividing by the 
total number of residues to obtain the average charge per residue. Kyte-Doolittle hydropathy was 
calculated for each region using a sliding window of 5 amino acids (226). Sequences were 
processed so that the sliding window did not include amino acids from separate regions. The 
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disorder/order boundary line is a modified version based on the original by Uversky and 
colleagues (109,115). 
Combined CH-CDF: While CH and CDF analyses are valuable separately, combination of these 
can yield even more information about the native state of a protein and roughly classify proteins 
as disordered (Q2), mixture of order and disorder (Q3), ordered (Q4), and rare (Q1) (227). Values 
for CH-CDF analysis were determined by calculating the distance between the selected point and 
the CH or CDF boundary line. 
Per-residue disorder prediction. Since factors that contribute to lack of native structure are mostly 
encoded in amino acid sequence, intrinsic disorder can be readily predicted using various 
computational tools. Certain prediction algorithms such as PONDR VL-XT can even identify 
functional features such as disorder-to-order transitions (often called molecular recognition 
features, or MoRFs). In order to predict level of disorder in single sequences, per-residue disorder 
predictors were used. Different predictors take different sequence characteristics into account, 
but all consider scores above 0.5 disordered, whereas scores below 0.5 are considered ordered. 
Two predictors were primarily used. PONDR VL-XT (108) is not the most accurate predictor, but 
is sensitive to local compositional biases. Therefore, it is useful for detection of potential 
interaction regions (125,228), which were determined with visual inspection. PONDR-FIT (185) is 
a meta-predictor which combines several individual predictors. As it utilizes several different input 
features for prediction, it achieves ~85% accuracy, which is more accurate than the individual 
predictors.  
Yeast strains, media, and microbiological techniques. The S. cerevisiae strains used in this study 
are described in Table 4.5.  
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Table 4.5: Yeast strains used in this study. 
 
Strain name Genotype 
RJY1277 MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-801 trp1-289 
ras1::HIS3 ras2::Ras2CS-Ext erf2::TRP1 〈YCp52RAS2〉 
RJY1330 MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-801 trp1-289 
ras1::HIS3 ras2::Ras2CS-Ext erf2::KANr 〈YCp52RAS2〉 
RJY1937 MATa ura3-52 trp1 lys2-801 leu2Δ1 his3Δ200 pep4Δ::HIS3 
prb1Δ1.6R can1 GAL cir+ erf2::KANr erf4::NATr 
RJY1944 MAT a leu2Δ1, ura3-52, lys2-80, ade2-101, trp1Δ63, his3Δ200 
erf2::KANr acc1::ACC1-TAP(HIS3) 
RJY1945 MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-801 ras1::HIS3 
ras2::Ras2CS-Ext erf2::TRP1 acc1::acc1-KANr 〈YCp52RAS2〉 
 
Plasmid construction. Plasmids that were used throughout this study are shown in Table 4.6. 
Base plasmids were designed through ligase-independent cloning via homologous recombination 
(229). Plasmids were rescued from yeast (230) and were sequenced to confirm deletions were in 
frame (GeneWiz). Mutations were introduced using the QuikChange XL II kit (Agilent) and were 
confirmed by DNA sequencing. The sequences of the deoxyoligonucleotide primers used to 
design the plasmids are available upon request. 
Table 4.6: Plasmids used in this study. 
Plasmids  Nickname Study 
pESC-Leu FLAG:ERF2 6xHIS:ERF4  This study 
pESC-Leu FLAG:ERF2  This study 
pESC-Leu FLAG:ERF2 6xHIS:ERF4  This study 
pESC-Leu FLAG:ERF2 (1-301) 6xHIS:ERF4 ΔallC This study 
pESC-Leu FLAG:ERF2 (Δ302-333) 6xHIS:ERF4 ΔCCR This study 
pESC-Leu FLAG:ERF2 (Δ334-359) 6xHIS:ERF4 ΔVarC This study 
pESC-Leu FLAG:ERF2 Y309A 6xHIS:ERF4  This study 
pESC-Leu FLAG:ERF2 S329A/S332A 6xHIS:ERF4 2A This study 
pESC-Leu FLAG:ERF2 Y309A/S329A/S332A 6xHIS:ERF4 2A/Y309A This study 
pEG(KT) GST:ERF4  This study 
pEG-MBP:mCherry:Ras2CT35  (83) 
pRS314 ERF2  This study 
pRS314 ERF2 C203S   This study 
pRS314 ERF2 Y309A   This study 
pESC-Trp ERF2  This study 
pESC-Trp ERF2 C203S   This study 
pESC-Trp ERF2 Y309A   This study 
pESC-Leu TAP  This study 
pESC-Leu TAP:ERF2  This study 
pESC-Leu TAP:ERF2 Y309A  This study 
pESC-Leu TAP:ERF2 S329A/S332A  This study 
pESC-Leu FLAG:ERF2   This study 
pESC-Leu FLAG:ERF2 (1-301)  ΔallC This study 
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Plasmids  Nickname Study 
pESC-Leu FLAG:ERF2 (Δ302-334)  ΔCCR This study 
pESC-Leu FLAG:ERF2 (1-334)  ΔVarC This study 
pESC-Leu FLAG:ERF2 Y309A   This study 
pESC-Trp FLAG:zDHHC9  This study 
pESC-Trp FLAG:zDHHC9 6xHIS:GCP16  This study 
pESC-Trp FLAG:zDHHC9 (C169A) 6xHIS:GCP16  This study 
pESC-Trp FLAG:zDHHC9 (1-260) 6xHIS:GCP16 ΔallC This study 
pESC-Trp FLAG:zDHHC9 (Δ261-310) 6xHIS:GCP16 ΔCCR This study 
pESC-Trp FLAG:zDHHC9 (1-310) 6xHIS:GCP16 ΔVarC This study 
pESC-Trp FLAG:zDHHC9 Y274A 6xHIS:GCP16  This study 
pESC-Leu FLAG:ERF2 (Δ1-15) 6xHIS:ERF4 D1 This study 
pESC-Leu FLAG:ERF2 (Δ348-359) 6xHIS:ERF4 D2 This study 
pESC-Leu FLAG:ERF2 (S329A) 6xHIS:ERF4 1A This study 
pESC-Leu FLAG:ERF2 (S313A/S329A/S332A) 6xHIS:ERF4 3A This study 
pESC-Leu FLAG:ERF2 (Δ1-15, Δ348-359) 6xHIS:ERF4 D1/D2 This study 
pESC-Leu FLAG:ERF2 (Δ1-15, Δ348-359) 6xHIS:ERF4 D1/D2/1A This study 
pESC-Leu FLAG:ERF2 (Δ1-15, Δ348-359) 6xHIS:ERF4 D1/D2/2A This study 
pESC-Leu FLAG:ERF2 (Δ1-15, Δ348-359) 6xHIS:ERF4 D1/D2/3A This study 
pESC-Leu FLAG:ERF2 (Δ348-359, S329A) 6xHIS:ERF4 D2/1A This study 
pESC-Leu FLAG:ERF2 (Δ348-359, S329A/S332A) 6xHIS:ERF4 D2/2A This study 
pESC-Leu FLAG:ERF2 (Δ348-359, S313A, S329A, S332A) 6xHIS:ERF4 D2/3A This study 
pESC-Trp FLAG:zDHHC9 myc:GCP16  This study 
pESC-Trp FLAG:zDHHC9 (1-260) myc:GCP16 ΔallC This study 
pESC-Trp myc:GCP16  This study 
 
Yeast complementation assay. The in vivo function of ERF2 was investigated using our previously 
described complementation assay (53). Plasmids were transformed into the appropriate 
complementation strain and plated on selective medium containing glucose. Colonies were 
inoculated into liquid selective medium containing glucose, and grown to a cell density (A600) of 
~2.0 at 30°C. 1:10 serial dilutions were made on selective medium plates containing glucose with 
or without 5’-FOA (1 g/L). Plates were grown for 3-5 days at 30°C or 37°C.   
Protein expression and purification of Erf2-Erf4 complexes. Strain RJY1937 was co-transformed 
with pESC-Leu(FLAG)Erf2-6XHIS-ERF4 and grown in SC(-Leu) medium containing 2% glucose 
at 30°C. The cultures were incubated to ~4 x 107 cells/mL, and then induced by subculturing 20mL 
of starter culture into 1L SC(-Leu) plus 2% galactose. Cells were induced for approximately 24h 
at 30°C, then harvested by centrifugation at 3000 x g for 5 min.  
All subsequent steps were performed at 4°C. Pelleted cells were resuspended in a 
purification buffer (100 mM Tris-HCl pH 8.5, 250 mL NaCl, 1 µM leupeptin, 2 µM pepstatin A, 1.6 
mM benzamidine). Cells were lysed with six passes through a LM10 microfluidizer (Microfluidics) 
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at 23,000 PSI. The lysed cells were spun at 3,000 g for 15 min to remove unbroken cells and 
debris, and the supernatant was centrifuged at 14,000 g for 30 min. The resulting membrane 
pellet was solubilized overnight in the purification buffer containing 10% glycerol and 1% n-
dodecyl-D-maltoside (DDM). Insoluble membranes were removed by repeating the 14,000 g spin. 
The supernatant was incubated with equilibrated Ni-NTA resin (5 Prime) for 3 hours with gentle 
rocking to isolate the enzyme complexes. Ni-NTA beads were washed with purification buffer plus 
0.03% DDM, and purified enzyme complexes were eluted using 300 mM imidazole.  
Gel-based transfer to Ras assay. MBP:mCherry:Ras2CT35 purifications were performed as 
previously described (83). Erf2 transfer to a Ras2 substrate was performed as previously 
described (83). Briefly, Bodipy C12:0-CoA (40uM final) was added to a 25uL reaction containing 
~2ug of purified enzyme and 100pmol purified MBP:mCherry:Ras2 in 0.05M sodium phosphate 
buffer, pH 6.8, and incubated at 30°C. After 30 min, 5X non-reducing loading buffer was added 
and each reaction was heated at 65°C for 3 min in order to stop the reaction. Samples were 
analyzed by SDS-PAGE (12%), and the gel was visualized on the Typhoon 9410 Variable Mode 
Imager (GE Healthcare) for Bodipy fluorescence (ex. 485nm/em. 528nm) to visualize transfer, 
which was observed as a shift of Bodipy C12:0-CoA signal from the enzyme molecular weight to 
the substrate molecular weight. Relative amounts of FLAG:Erf2 and MBP:mCherry:Ras2 were 
determined via total protein stain and mCherry fluorescence, respectively. 
Circular dichroism. Far-UV CD (195-260nm) spectra was measured using a JASCO J-815 
spectropolarimeter at room temperature. Purified peptides were dissolved in 20 mM SPB pH 7.5 
(0.25 mg/mL) and were placed in a 0.2mm pathlength cell, and CD spectra were acquired with 
20nm/min scan speed at 0.1 nm step size and 1.0 nm bandwidth under constant purging with 
nitrogen. Three spectra were accumulated and averaged for each sample.  
Tandem affinity purification. N-terminal TAP tagged Erf2 constructs (Protein A-TEV-CBP-Erf2) 
and GST-myc-Erf4 were transformed into strain RJY1937. Purification was performed essentially 
as described previously, with a few modifications. All steps were performed at 4°C unless 
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otherwise stated. Cells were broken using a LM10 Microfluidizer (Microfluidics) in YEB Buffer (250 
mM KCl, 5 mM EDTA, 5 mM EGTA-NaOH, 10 mM HEPES-KOH, pH 7.9) with 2.5 mM DTT added 
fresh. After six passes, the extracts were briefly spun (3000 x g, 10 min), and solubilized overnight 
in either Triton X-100, DDM, or C12E8 (1% each). Solubilized extracts were spun at 100,000 x g 
for 1 hour to remove insoluble protein. IgG Sepharose (GE Healthcare) was equilibrated in IPP 
buffer (10 mM Tris-HCl pH 8, 100 mM NaCl) plus 0.1% of the appropriate detergent, and the resin 
was added to each solubilized extract for three hours. After five washes in IPP buffer and two 
washes in TEV cleavage buffer (50mM Tris-HCl pH 8, 0.2 mM EDTA, 100 mM NaCl, 1 mM DTT) 
plus 0.1% detergent, TEV protease was added and incubated overnight to remove the Protein A 
tag. One volume of CBB Buffer (10 mM Tris-HCl pH 8, 100 mM NaCl, 2 mM CaCl2, and 0.7% 2-
Me) plus 0.1% detergent and 0.75 mM CaCl2 were added to each eluate, and calmodulin resin 
equilibrated in CBB buffer plus 0.1% detergent was added to each sample and rotated for 2 hours. 
Beads were washed five times with CBB buffer and three times with calmodulin wash buffer 
(10mM Tris-HCl pH 8, 100mM NaCl, 0.1mM CaCl2, 0.7% 2-Me). Protein attached to the washed 
resin was eluted with calmodulin elution buffer (10 mM Tris-HCl pH 7.9, 100 mM NaCl, 3 mM 
EGTA, 0.7% 2-Me). The eluate was lyophilized and subsequently resuspended in SDS loading 
buffer. Samples were run on a 4-20% gradient gel, and gel fragments were digested with trypsin 
and subjected to LC-MS/MS. 
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CHAPTER 5 
 
Regulation of the Synapse by zDHHC9, the Ras PAT 
 
5.1 Introduction 
Learning, memory, and motor functions are coordinated by polarized neurons in the adult 
hippocampus, which transmit information to other neurons via precisely timed chemical and 
electrical signals. Communication between neurons occurs at the synapse where the axon of one 
neuron (presynaptic terminal) transmits chemical and electrical signals to the dendrites of another 
neuron (postsynaptic terminal). The subsets of proteins required at the membranes of each 
terminal for synaptic transmission are unique in their identities and functions. Presynaptic proteins 
generally regulate neurotransmitter synthesis, synaptic vesicle fusion, and transmitter release, 
while postsynaptic proteins consist of neurotransmitter receptors, scaffolds, and signaling 
proteins (68). Therefore, the formation of a functional synapse requires precise spatiotemporal 
control of protein localization in the neuron.  
S-palmitoylation has emerged as one of the prominent regulators of protein sorting in 
neurons (68). Over 300 candidate palmitoylated proteins have been identified in synaptosomal 
membranes of rat cortical neurons (231), and these regulate essential synaptic events such as 
vesicle trafficking, ion transport, adhesion, and scaffolding. As palmitoylation alters protein 
function through facilitation of membrane attachment/distribution, subcellular trafficking, and 
stability (8), it  likely serves a broad role in synapse morphology and function (68).  
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PATs play important roles in synaptic function through palmitoylation of substrates such 
as PSD-95, ionotropic glutamate receptors, and SNAREs (68,231,232). However, the association 
between zDHHC genes and clinical neurological phenotypes have only just begun to emerge. 
Two PAT genes (zDHHC9, zDHHC15) are among a group of >110 genes on the X-chromosome 
that have been associated with X-linked intellectual disabilities (XLID), which includes over 200 
syndromes and accounts for approximately 16% of intellectual deficiencies in males (233,234). 
While a subsequent study failed to support the association between XLID and zDHHC15 (235), 
genetic and biochemical evidence strongly suggest a role for zDHHC9 in XLID (233,236,237).  Of 
the XLID associated mutations in zDHHC9, two delete the majority of the protein coding region, 
and two missense mutations, R148W and P150S, result in decrease in steady-state 
autopalmitoylation activity of zDHHC9 (238). These observations have led to a hypothesis that 
reduced palmitoylation of zDHHC9 substrate(s) results in XLID.  However, the role and 
importance of zDHHC9 in neurons has yet to be established, which is critical to understanding its 
role in the pathophysiology of XLID. 
In this study, we determined the general characteristics of zDHHC9 in the brain and 
characterized a newly described XLID-associated mutation, R298* (237). Unlike the previously 
characterized zDHHC9 mutations, this truncation appeared to have normal PAT activity and 
kinetics. Unlike previously characterized mutations, this truncation appears to have normal PAT 
activity and kinetics, but instead, displays restricted vesicle-mediated transport to and from 
dendrites and axons compared to wild-type protein. Based on the characterization of this and 
other clinical zDHHC9 mutants, we conclude that enzyme activity and subcellular localization are 
required to palmitoylate target proteins involved in synaptic development and/or function.   
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5.2 General Characteristics of zDHHC9 in the Brain  
5.2.1 zDHHC9 is Consistently and Highly Expressed in the Brain 
 Comparison of zDHHC protein expression in the human proteome reveals that zDHHC9 
is one of the most highly expressed zDHHC proteins in the adult frontal cortex, in addition to 
zDHHC5 and zDHHC14 (Fig. 5.1) (239). Using anti-zDHHC9 specific antibodies (Fig. 5.2A), we 
observed relative expression in adult mouse tissue homogenates revealed that the brain had 
much higher expression of zDHHC9 compared to heart, liver, kidney, lung, and stomach (Fig. 
5.2B). Tissue homogenates from early to late stages of mouse development had relatively 
consistent zDHHC9 expression compared to H-Ras (Fig. 5.2C). 
 
 
 
 
 
 
 
 
 
Figure 5.1: Relative protein expression of zDHHC proteins in various mammalian tissues. Red intensity 
represents protein expression. Figure was created using the Human Proteome Map (233).  
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5.2.2 zDHHC9 is Ubiquitously Expressed Throughout Neuronal Membranes 
In previous studies, zDHHC9 was found to localize to the Golgi in HeLa and HEK293T 
cells (19,58).  We found that zDHHC9 is enriched in Golgi, presynaptic, and postsynaptic fractions 
from rat brains (Fig. 5.3). Immunofluorescence studies of endogenous zDHHC9 in neurons were 
inconclusive due to limitations of specificity of the anti-zDHHC9 specific antibody. 
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Figure 5.3: Endogenous zDHHC9 is found in all major neuronal compartments. zDHHC9 was enriched in the P3 
fraction, presynaptic-enriched fraction (Sol), and postsynaptic-enriched fraction (PSD1 and PSD2). H, homogenate; S, 
supernatant; P, pellet; synaptosome; Sol, Triton X-100 soluble; PSD, Triton X-100–insoluble postsynaptic density 
fractions. 
Figure 5.2: Characterization of zDHHC9 and H-Ras in mouse tissue. (A) Validation of antibody specificity to 
zDHHC9 in HEK293T cells , using shRNA targeted to zDHHC9 (Sigma-Aldrich, TRCN0000193342). (B) Relative tissue 
expression of zDHHC9 and H-Ras in an adult female mouse. (C) Expression of zDHHC9 and H-Ras in mouse 
development.  
A B C 
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5.2.3 zDHHC9 is Highly Palmitoylated in Rat Brain 
 It has been previously speculated that zDHHC proteins themselves can be substrates for 
palmitoylation, although the potential functional consequences of this phenomenon are unclear. 
We examined the palmitoylation state of zDHHC9 in rat brain using the acyl-PEGyl exchange 
assay (APE, or APEGS) (12,40). This assay is based on the principle of replacing palmitates with 
polyethylene glycol polymers, and observing the resulting mass shift on an SDS-PAGE gel. We 
observe at least four distinct species of palmitoylated zDHHC9 using this assay, with the total 
mass shift suggesting at least 10 out of 12 possible palmitate modifications (Fig. 5.4).  
5.3 The Molecular Defect of zDHHC9 R298*, an XLID-Associated Mutation 
5.3.1 zDHHC9 R298* Removes a Non-Conserved Region Predicted to be Disordered 
The corresponding residue affected by the nonsense mutation, Arg298, is located 40 
residues beyond a conserved Thr-Thr-x-Glu motif found after the last TMD in zDHHC PATs (Fig. 
5.5A). Full-length zDHHC9 was analyzed by intrinsic disorder predictors, and it was found that 
the region removed by the nonsense mutation, 298-364, is predicted to be intrinsically disordered 
and located directly after the CCR and proposed regulatory Sxx[S/D] motif described in the 
previous chapter (Fig. 5.5A). The region removed by R298* is not conserved between PAT 
orthologs zDHHC14 and zDHHC18 (Fig. 5.5B), and it is therefore possible that this region 
encodes a zDHHC9-specific regulatory feature.  
Figure 5.4: zDHHC9 is highly palmitoylated in rat brain. APEGs assay of wild-type rat brain homogenates reveals 
that zDHHC9 is highly modified. PEG-malemide polymer is ~ 2kDa, and zDHHC9 appears to shift at least 20kDa.  
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To begin to address the functional significance of the R298* allele, GFP-zDHHC9 (WT 
and R298*) were expressed in HEK293T cells. GFP was N-terminally tagged to zDHHC9, as C-
terminal GFP tags have been observed by us and others to interfere with the localization and 
function of zDHHC proteins. We found that R298* was expressed to approximately the same 
levels compared to wild-type (Fig. 5.6) and there was no presence of higher molecular weight 
species characteristic of SDS-resistant aggregation. Although zDHHC9 was previously identified 
as a potentially ubiquitinated protein in several high-throughput studies (84-87), we find no 
evidence of a corresponding mass shift. While zDHHC9 is highly palmitoylated, no cysteines are 
present in the region deleted by R298*; however, further analysis of R298* is needed to verify 
that the R298* does not affect the zDHHC9 palmitoylation state.  
Figure 5.5: General characterization of zDHHC9 R298*. (A) Intrinsic disorder prediction of human zDHHC9 by 
PONDR-FIT (dashed red) and PONDR VL-XT (solid black). Scores above 0.5 are predicted to be disordered, while 
scores below 0.5 are predicted to be ordered. Transmembrane domains (TMDs) are indicated in red and the catalytic 
DHHC cysteine-rich domain (CRD) is indicated in yellow. (B) Conservation of the C-termini of Ras PAT homologs 
zDHHC9, zDHHC14, and zDHHC18. The green box surrounding the TTxE motif indicates the start of the C-terminus. 
A 
B 
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5.3.2 zDHHC9 R298* is a Loss-Of-Function Mutation That Does Not Affect Catalytic 
Activity 
We performed a heterologous genetic assay in yeast to test the Ras PAT activity of 
zDHHC9 in cells, based on the observation that wild-type zDHHC9 can partially complement the 
loss of Erf2 in the presence of its regulatory subunit, Gcp16 (238) (Fig. 5.7). Though the R298* 
mutant has comparable expression compared to the wild-type protein, it cannot functionally 
replace the loss of Erf2, suggesting that R298* is a loss-of-function allele that diminishes 
palmitoylation-dependent Ras function in cells.   
 
Figure 5.6: Truncation of zDHHC9 does not affect protein expression. GFP-tagged zDHHC9 wild-type and R298* 
were individually transfected in HEK293T cells. Proteins were separated by SDS-PAGE, followed by western blotting 
with GFP and β-catenin antibodies. 
Figure 5.7: zDHHC9 R298* is a loss-of-function allele. Complementation assay to assess the ability of ZDHHC9-
GCP16 to suppress the loss of ERF2 in S. cerevisiae. Strain RJY1330 (MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-
801 ras1::HIS3 ras2::Ras2CS-Ext erf2::KANr 〈YCp52RAS2〉) harboring plasmids pESC-TRP based plasmids were 
monitored for RAS2-independent growth as described previously. C169A is the catalytically inactive ‘DHHA’ mutant. 
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Despite the loss in palmitoylation-dependent Ras function, we suspected that this mutant 
would behave similarly to wild-type protein in biochemical assays since the nonsense mutation 
R298* does not appear to remove conserved regions or any known critical features for PAT 
activity. We performed a previously validated in-gel assay of palmitoylation using BODIPY® 
C12:0-CoA, a fluorescent analog of palmitoyl-CoA (83). When compared to wild-type, we found 
that R298* had approximately the same levels of steady-state autopalmitoylation as the wild-type 
protein (Fig. 5.8A, B), and equal levels of interaction with its cofactor, Gcp16.  
5.3.4 zDHHC9 R298* Has Restricted Trafficking to Dendrites and Axons 
As would be predicted by the subcellular fractionation data of endogenous zDHHC9, GFP-
tagged zDHHC9 is found in the cell body, dendrites, and axons, indicating that GFP-tagged 
zDHHC9 is correctly localized. GFP-zDHHC9 puncta in dendrites and axons are observed to 
move both anterograde and retrograde (Fig. 5.9A). In contrast, the zDHHC9 R298* mutant protein 
is restricted to the cell body (Fig. 5.9B, C).   
Figure 5.8: zDHHC9 R298* has no apparent effect on enzyme activity. (A) Representative steady-state 
autopalmitoylation reactions of wild-type and R298* zDHHC9, using BODIPY C12:0-CoA as the acyl donor. (B) 
Quantitative analysis of Figure 2B, representing the ratio of BODIPY-zDHHC9 to total protein (n=3). 
A B 
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5.4 Discussion 
The 23 mammalian PATs have varying degrees of substrate specificity, and individual 
PATs target multiple substrates (59). One of the factors that regulate the distribution of 
palmitoylated proteins in the neuron appears to be subcellular localization of the PAT. For 
example, Golgi-localized PATs such as zDHHC3 cotranslationally palmitoylate substrates 
resulting in membrane targeting (66). When a palmitoylated protein reaches its destination, PATs 
Figure 5.9: zDHHC9 localization and trafficking in rat hippocampal neurons. (A) Colocalization of GFP-zDHHC9 
R298* with GM130. (B) GFP-zDHHC9 localizes to the Golgi and mobile punctate spots (arrows) in axons and dendrites.  
GFP-zDHHC9 (R298*) localization is restricted to the cell body. Pictures are representative of 0 and 10 minutes. (C) 
Quantitation of the ratio of fluorescence in neuronal outgrowths (dendrites and axons) to the cell body (p=0.04, n=3).   
 
A 
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and depalmitoylation enzymes specifically localized to the presynaptic and postsynaptic terminals 
maintain the equilibrium of palmitoylated and non-palmitoylated protein (12,66,67). However, the 
redundancy of PATs has also been well characterized, and an unanswered issue in the field is 
the importance of PAT localization compared to enzymatic activity. 
In this study, we demonstrate that zDHHC9 moves dynamically to and from dendrites and 
axons, presumably through vesicle-mediated trafficking. In other zDHHC proteins, synaptic 
activity can result in a dynamic relocalization of PATs, which can in turn affect function. For 
example, when synaptic activity is inhibited, zDHHC2 moves from the dendrites to the 
postsynaptic membranes, resulting in accumulation of membrane-bound PSD-95 and subsequent 
increase in AMPAR-mediated synaptic transmission (66). Therefore, activity-dependent 
palmitoylation of PSD-95 maintains downstream AMPAR homeostasis. Potentially, zDHHC9 
localization could be regulated by similar mechanisms to help coordinate synaptic signals. More 
generally, as it is known that synaptic vesicles have distinct pools with unique protein composition 
(240,241), comparison of the effects of synaptic activity on the localization of different zDHHC 
proteins may increase understanding of the overall palmitoylation dynamic in the neuron. 
Once zDHHC9 gets to its destination, it can potentially palmitoylate a number of 
substrates. A primary role for zDHHC9 is likely palmitoylation of its known cognate substrate, H-
Ras, which has been shown to be essential to learning, memory, and synaptic function (242-245). 
Alternatively, the apparent relatively high expression of zDHHC9 in the brain compared to other 
PATs (239), together with its relatively ubiquitous localization in neurons, perhaps suggests a 
broader role for this enzyme towards other synaptic substrates. To our knowledge, zDHHC9 has 
only been identified once in overexpression studies to determine PAT specificity to substrates 
(65). Among several reasons, this may be explained by redundancy of PAT function, the lack of 
spatiotemporal context that primary neurons provide, or that its required cofactor Gcp16 is hardly 
ever considered in overexpression studies. Clearly, more investigation is required to distinguish 
these possibilities. 
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Understanding the relationship between substrates and activity-regulated zDHHC9 
localization will be critical to understanding the overall role of zDHHC9 in neuronal development 
and function. Our differential expression data demonstrated that zDHHC9 expression is relatively 
consistent throughout development, perhaps suggesting that zDHHC9 is important in not only 
neurodevelopmental processes (such as dendritogenesis, spinogenesis, or axon outgrowth), but 
also for maintenance of synaptic function and therefore long-term potentiation (LTP) or long-term 
depression (LTD). zDHHC9’s role in maintaining intellectual abilities could also be attributed to 
non-neuronal cells such as glial cells. While our observations would suggest that this is unlikely, 
analyzing palmitoylation levels in different brain compartments of wild-type versus knockout mice, 
together with electrophysiological experiments would be required to truly resolve these issues. 
Further refining and answering these general questions will ultimately help understand 
why defects in zDHHC9 are associated with XLID. Previously, we demonstrated that missense 
mutations in the zDHHC9 CRD alter autopalmitoylation activity and presumably substrate 
palmitoylation. A nonsense mutation associated with a clinical manifestation of XLID (R298*) 
removed a small, variable, presumably disordered region from the C-terminus. Similarly, variable 
C-termini of some zDHHC proteins regulate their subcellular localization (80,81). Therefore, we 
hypothesized that deletion of this region would regulate localization but not steady-state 
autopalmitoylation, and our findings appear to support this hypothesis. There are no cases of 
active-site mutations affecting PAT localization; however, whether or not regions important for 
localization affect enzyme activity has not been examined.  
As this mutation is associated with a neurodevelopmental disorder, this raises the 
possibility that in addition to enzyme activity, localization of zDHHC9 to presynaptic and/or 
postsynaptic membranes is important for synapse formation, organization, and/or function. The 
dramatic clinical effects of this nonsense mutation raises many basic questions regarding 
regulation of zDHHC9 localization by the variable C-terminus. Potentially, this region could be 
associated with protein-protein interactions and/or post-translational modifications that regulate 
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vesicle-mediated membrane trafficking. While we have demonstrated that zDHHC9 is highly 
palmitoylated, no cysteines are present in the region removed by R298*, and therefore another 
mechanistic process is likely involved in the molecular defect caused by R298*. 
Further characterization of the relationship between palmitoylation and XLID may be 
essential to elucidating pathways and designing pharmacological modulators. Of the 114 genes 
that are currently used to screen for XLID in patients (Greenwood Genetic Center, Greenwood, 
SC), 24 encode known palmitoylated proteins – a higher number than expected, considering that 
~10% of the proteome is estimated to be palmitoylated (46,47). An additional 54 of these genes 
encode proteins that are predicted to be palmitoylated by both CSS-Palm and PalmPred 
(46,188,201) (Fig. 5.10). While these known and putative substrates may be palmitoylated by 
different enzymes, they represent a starting point to understand how the function of synaptic 
proteins are affected by palmitoylation, and therefore what signaling pathways affected by 
palmitoylation are required to maintain intellectual abilities.  
 
 
 
 
Figure 5.10: Analysis of XLID genes. (A) Top five GO terms enriched in 114 XLID genes. (B) XLID proteins known, 
predicted, and unknown to be palmitoylated. Proteins were categorized as ‘predicted’ if predicted by both PalmPred 
and CSS-Palm. 
A B 
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5.5 Experimental Procedures 
Acyl-PEGyl exchange. This procedure was performed essentially as described (12,40). One adult 
female rat brain was homogenized (4% SDS, 5 mM EDTA, protease inhibitor). After sonication 
and centrifugation (100,000 x g, 15 min), 150 µg of protein was reduced with 25 mM TCEP for 1 
hour at 55°C. Resulting free thiols were blocked with NEM (3 hours at RT). After 
chloroform/methanol precipitation, palmitates were cleaved using 1 M hydroxylamine (1 hour, 
37°C). After another chloroform/methanol precipitation, 50 µg of proteins containing free thiols at 
formerly palmitoylated residues only were either blocked using 20 mM NEM or PEGylated using 
20 mM of a 2 kDa PEG-maleimide. After a final chloroform/methanol precipitation, proteins were 
resuspended in SDS sample buffer, heated for 100°C for 5 min, and run on SDS PAGE. 
Plasmid construction. pCAG-GFP was a gift from Connie Cepko (Addgene plasmid #11150). All 
ligation reactions were performed using T4 DNA ligase (Promega). GFP-tagged zDHHC9 
plasmids were constructed so that the GFP gene was attached in frame to the 5’ end of the 
zDHHC9 allele. All yeast vectors were designed through homologous recombination. The DNA 
sequences of all constructs were verified by DNA sequencing (GeneWiz, Plainfield, NJ). Primer 
sequences are available upon request. 
Protein Expression and Purification—zDHHC9-GCP16 enzyme complexes were expressed from 
the pESC(Trp)-divergent GAL1,10 promoter in strain BJ5459 (MATa, ura3–52, trp1, lys2-
801, leu2Δ1, his3Δ200,pep4::HIS3, prb1Δ1.6R, can1 GAL) (238,246). Yeast cultures were grown 
in synthetic complete (SC) medium lacking tryptophan plus 2% glucose for cell growth or YEP 
medium (1% yeast extract, 2% peptone) plus 2% galactose for promoter induction.  
All subsequent steps were performed at 4°C. Pelleted cells were resuspended in a 
purification buffer (100 mM Tris-HCl pH 8.5, 250 mL NaCl, 1 µM leupeptin, 2 µM pepstatin A, 1.6 
mM benzamidine). Cells were lysed with six passes through a LM10 microfluidizer (Microfluidics) 
at 23,000 PSI. The lysed cells were spun at 3,000 g for 15 min to remove unbroken cells and 
debris, and the supernatant was centrifuged at 14,000 g for 30 min. The resulting membrane 
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pellet was solubilized overnight in the purification buffer containing 10% glycerol, 0.2% cholesteryl 
hemisuccinate, and 1% n-dodecyl-D-maltoside (DDM). Insoluble membranes were removed by 
repeating the 14,000 g spin. The supernatant was incubated with equilibrated Anti-FLAG M2 
Affinity Gel (Sigma-Aldrich) overnight with gentle rocking to isolate FLAG-tagged enzymes. FLAG 
beads were washed with 20mM Tris-HCl, 150mM NaCl, 0.03% DDM. Purified enzyme complexes 
remained bound to FLAG beads for further analysis. 
In-gel fluorescence assay of palmitoyltransferase activity. This assay has been described 
previously (83,238). The synthesis of BODIPY® C12:0-CoA from BODIPY® C12:0 (Invitrogen) 
and CoASH (Sigma) has been previously described (83,247). BODIPY® C12:0-CoA (40 µM final) 
was added to a reaction containing ~2 ug enzyme in 50 mM sodium phosphate buffer (pH 6.8). 
The reaction was incubated for 30°C for 5 min, and subsequently stopped by adding 5X non-
reducing SDS sample buffer. The reaction was heated at 70°C for 5 min and run on an SDS-
PAGE gel containing 0.5% 2,2,2-Trichloroethanol (v/v) to enable visualization of total protein 
(248). Transfer of the BODIPY® signal (488 nm excitation/532 nm emission) was imaged on the 
Typhoon 9410 variable mode imager (GE Healthcare), and total protein (UV) was visualized on a 
ChemiDoc XRS+ (Bio-Rad). 
Subcellular fractionation. The method was performed as described previously (66). The rat brain 
homogenate (in homogenization buffer: 320 mM sucrose, 1 mM HEPES-NaOH, pH 7.4, 0.2 mM 
PMSF) was centrifuged (10 min, 1,000 g), which yielded a crude nuclear fraction (P1) and a 
supernatant (S1). Centrifugation of the S1 (9,000 g, 15 min) yielded a pellet (P2) and supernatant 
(S2). Centrifugation of the S2 (100,000 g, 1 hr) yielded a pellet (P3; microsomal fraction) and 
supernatant (S3; cytoplasmic fraction). Using discontinuous sucrose gradients (0.8/1.0/1.2 M 
sucrose, 10mM HEPES-NaOH pH 7.4), centrifugation of homogenized P2 (58,000 g, 2 hr) yielded 
a synaptosome fraction (band between 1.0 M and 1.2 M sucrose). Extracted synaptosome fraction 
(0.5% Triton X-100, 0.16 M sucrose, 6 mM Tris-HCl pH 8.1) was centrifuged (32,800 g, 20 min), 
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which yielded a soluble (sol; presynaptic-enriched) and insoluble pellet (Ins1; PSD-1). The pellet 
was again extracted and centrifuged (200,000 g, 1 hr) to yield another pellet (Ins2; PSD-2).  
Neuronal cell culture and imaging.  Rat hippocampal neurons (Wistar, E18-19) were isolated and 
plated to a density of 2.5 x 105 cells per poly-L-lysine-treated glass-bottom dish and cultured in 
neurobasal medium (Invitrogen) supplemented with B-27 and 2 mM Glutamax (Gibco). After 5 
days, plasmids were transfected into neurons using Lipofectamine 2000 (Thermo Fisher 
Scientific), and cells were incubated for one week. Time-lapse imaging was performed on a TCS 
SP5 II confocal microscope (Leica). The objective lens used was an HCX PL APO 63×/1.40 NA 
oil. 3D image stacks were taken and then projected to 2D images using maximal intensity. Our 
observations were consistent between three separate hippocampal neuron preparations, with 
approximately 5-10 neurons observed per transfection. All animal studies described herein were 
reviewed and approved by the ethics committee at our institution (IACUC #R-IS00001256). 
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CHAPTER 6 
 
Discussion and Perspectives 
 
6.1 Regulation of Palmitoylation 
 The field of palmitoylation is still in the early stages. The enzymes were discovered less 
than 15 years ago, and there is still no crystal structure of a palmitoyltransferase nor are there 
any specific chemical probes or modulators, leaving a gap in our knowledge of the mechanism.  
Also, while our knowledge of palmitoylated substrates has been rapidly growing, we have an 
incomplete understanding about the physiological interplay between enzymes and substrates.  
Finally, it is also clear that the full repertoire of depalmitoylation enzymes have yet to be 
discovered. Compared to the discovery of kinases in the mid-1950s (249), the discovery of 
palmitoyltransferases in the early 2000s is about 40-50 years ‘behind’, though this difference is 
likely lessened by rapid advances in techniques and understanding of biology. Kinases and other 
well-characterized post-translational modification enzymes can be regulated by a number of 
factors, including post-translational modifications, protein-protein interactions, etc. Likely, 
palmitoyltransferases can be regulated to a similar extent, and some instances of this have been 
described in the literature. 
 The work described in this dissertation has begun to uncover previously unappreciated 
regulatory mechanisms. Primarily, I addressed a potential linkage between palmitoyltransferase 
activity and fatty acid metabolism pathway(s), through direct interaction of a PAT with Acc1, an 
enzyme critical to de novo fatty acid synthesis. While it is possible that all PATs interact with Acc1, 
sequence analysis suggests that the more likely scenario is that only a subset of PATs do this – 
at least Ras PATs, if not other PATs containing a CCR with a PaCCT motif. Presumably, because 
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of the well-conserved C-termini of PATs, these regions or others may interact with proteins that 
are similar functionally (i.e. maintaining local fatty acid levels). Therefore, a logical supposition 
would be that PATs can also be linked to other enzymes involved in fatty acid synthesis, or even 
those that activate exogenous fatty acids – in yeast, Faa1 and Faa4.  
 Our model suggests that the Erf2-Acc1 interaction may be dynamically altered by 
phosphorylation at conserved serines proximal to the carboxy-end of the CCR, Ser329/Ser332. 
We propose that this would serve as an electrostatic switch to shift the equilibrium of the CCR 
from membrane-bound to non-membrane bound state, destabilizing the CCR helix and 
decreasing binding affinity towards Acc1 and/or other interactors. If correct, then decreasing 
expression of a specific kinase or phosphatase would theoretically increase or decrease 
palmitoyltransferase catalysis rates, respectively. There are few other instances of 
phosphorylation of PATs affecting function. Tyrosine phosphorylation of zDHHC5 reduces 
interaction levels with AP2, stabilizing zDHHC5 at the synaptic membrane (89). This tyrosine is 
within a canonical AP2 binding motif and therefore unlike our proposed mechanism for Erf2, it is 
likely that tyrosine phosphorylation directly interferes with the binding site. 
Ultimately, phosphorylation of Ras PATs may prove to be another level of spatiotemporal 
control of palmitoylation in the cell, in addition to localization and tissue-specific expression. As a 
representative example, kinase activity is controlled in response to events such as external stimuli 
and changes in the cell cycle, and presumably PATs can be similarly tuned. Identification and 
expression-profiling of the specific kinases and phosphatases that control CCR-membrane 
interaction would clarify these possibilities. Based on sequence analysis, other closely-related 
PAT C-termini do not have similarly conserved proximal residues likely to be post-translationally 
modified; therefore, this subset may represent ‘constitutively active’ PATs. Alternatively, the 
interactions of these CCRs may be regulated by other mechanisms such as crowding. To add an 
additional layer of complexity, I have already proposed the idea that this potential switch may also 
be tuned by palmitoylation in more advanced organisms. This possibility is intriguing as a potential 
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biochemical framework of reversible palmitoylation substituting for reversible phosphorylation 
through evolution. There are a few instances of phosphorylation modulating intrinsic disorder, by 
either promoting interaction with a partner, recognition of a modified partner, or direct induction of 
folding (141,143,250). While much less has been published regarding other modifications, they 
can presumably affect the structure of a disordered region in similar ways. 
 I have also detected several other modifications in the Erf2 C-terminus, both within and 
outside the MoRF. I have determined that phosphorylation within the first 15 residues of Erf2 
result in the observed mass shift. However, no function has been attributed to these residues, 
and it is likely that this region has no functional consequences. Much of the phosphorylation found 
in the cell is likely to be non-functional (251), and our observations may also be an artifact of 
overexpression. Unexpectedly, I found four acetylated lysine modifications in the Erf2 C-terminus, 
both within and outside the MoRF. Previous studies from our laboratory have demonstrated that 
a subset of six lysines in the C-terminus are ubiquitinated, and result in ubiquitin-mediated 
degradation. Interplay between acetylation and ubiquitination has been shown in other systems 
to alter the equilibrium of protein stability (252), and it is possible that similar mechanisms occur 
in zDHHC PATs.  
Furthermore, the one acetylated lysine found within the CCR is projected to be within the 
hydrophobic face of the CCR. Therefore, lysine modification propensity may be further regulated 
by C-terminal phosphorylation. In this model, the lysine of the membrane-bound CCR 
(dephosphorylated Erf2) would not be exposed to modification, and would require a 
phosphorylation event for solvent exposure. While this idea would be an extremely interesting 
biochemical mechanism, this lysine is not present in zDHHC9, and therefore this mode of 
regulation would likely not be directly conserved.  
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6.2 The Potential of Palmitoylation as a Therapeutic Target   
 In this dissertation, I have extensively focused on the association of zDHHC9 and X-
Linked Intellectual Disabilities; however, mutations and changes in expression of the zDHHC 
family of genes are associated with several diseases including multiple types of cancer, 
neurological disorders, and infectious diseases. The known enzyme-disease associations have 
been extensively covered in the literature and are summarized in Table 6.1 (68). Since it is 
estimated that 10% of the eukaryotic proteome is palmitoylated, discovery of molecules that could 
modulate PAT function in the cell are of interest to not only the palmitoylation field, but the general 
scientific community.  
Table 6.1: zDHHC genes implicated in disease. Proposed mechanisms include increase in expression (1), increase 
in activity (2), decrease in expression (3), and decreas e in activity (4). Adapted from (68). 
 
 
Gene 
 
Disease/Disorder 
 
Substrate(s) 
 
Proposed 
Mechanism 
 
Reference 
zDHHC2 Gastric Cancer unknown 3 (253) 
zDHHC3 Cervical Cancer unknown 3 (254) 
zDHHC5 Schizophrenia GRIP1b 1 (74) 
zDHHC7 Breast Cancer AR, ERα, PR 
 
1 or 2 (255-257) 
zDHHC8 Schizophrenia GRIP1b 3 (74) 
zDHHC9 Colorectal Cancer 
Gastric Cancer 
X-Linked Intellectual Disability 
H- and N-Ras 
 
1 
1 
4 
(258) 
(258) 
(233,238,259) 
zDHHC11 Non-Small-Cell Lung Cancer unknown 1 (260) 
zDHHC12 Alzheimer's Disease APP 1 (261) 
zDHHC13 Huntington’s Disease 
Osteoporosis (mouse) 
Htt, GLT-1, 
SNAP-25 
3 or 4 
3 
(21,262,263) 
(264,265) 
zDHHC14 Acute Myeloid Leukemia 
Gastric Cancer 
Lymphomas 
Testicular Germ Cell Tumors 
unknown 2 
1 
1 
3 
(266) 
(267) 
(268) 
(269) 
zDHHC15 X-Linked Intellectual Disability unknown 4 (234,259) 
zDHHC16 Apoptosis Regulation c-Abl 1 (270) 
zDHHC17 Huntington’s Disease Htt, GLT-1, 
GAD65 
3 or 4 (21,76,262,271-
275) 
zDHHC21 Breast Cancer AR, ERα, PR 1 or 2 (255-257) 
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Several issues have to be taken into consideration when considering PATs as small-
molecule targets. Firstly, both activators and inhibitors are both useful, as both upregulation and 
downregulation of PAT expression is associated with disease. Also, considering the redundancy 
of PAT function and the high homology between the family, the ideal clinical modulator of a PAT 
would be highly specific for the PAT. Significant efforts in our laboratory and others are dedicated 
to therapeutic interventions of PATs (79,276). Currently, the standard inhibitor of palmitoylation 
used in published research is 2-bromopalmitate, which is proposed to act as a pan-inhibitor of 
zDHHC enzymes through irreversible covalent linkage to the DHHC cysteine (277). However, this 
molecule has been shown to have low affinity towards PATs and is extremely non-specific, 
targeting a diverse set of thiol-containing proteins other than zDHHC proteins (278). Therefore, 
other avenues of small-molecule modulation of PATs are of interest. 
It remains to be seen if individual PATs, let alone specific PAT-substrate interactions, can 
be targeted by small molecules. These distinctions would be critical for therapeutic development. 
For example, as T. gondii zDHHC7 is critical for apical rhoptry tethering (69), an ideal intervention 
towards toxoplasmosis would be an inhibitor that could target T. gondii zDHHC7 with much 
greater affinity than human zDHHC7. While our group has recently identified a family of bis-
piperazines that target the autopalmitoylation step of Erf2 using a high-throughput approach, it is 
proposed that these molecules act as pan-zDHHC inhibitors (276). This may be useful as a 
chemical probe in the future; however, more drug discovery efforts are required to determine if 
this class of molecules can possibly be refined into PAT-specific inhibitors. Likely, more structural 
information is required for development of small molecules that are able to discern between PATs.  
 As PATs have high homology within the CRD, a very possible scenario is that targeting 
this domain may not yield PAT-specific inhibitors. If so, alternative methods of targeting PATs will 
need to be identified. While still in early stages, the research presented in this dissertation can 
potentially be an alternative framework of targeting PATs. For instance, if post-translational 
modifications of zDHHC PATs do indeed modulate reaction rates or stability, finding and targeting 
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the specific modification enzymes may be a straightforward approach. In particular, targeting 
phosphorylation would be interesting as several specific inhibitors of kinases and phosphatases 
have already been identified and are approved in the clinic. In our proposed model, inhibiting 
kinases specific towards particular PATs would be a potential avenue of increasing PAT activity, 
which would be especially advantageous as several disease phenotypes are correlated with 
decreased PAT expression.  
 Designing small molecules towards protein-protein interfaces and disordered regions can 
be associated with a number of challenges (279). However, the CCR and other MoRFs of PATs 
may be interesting from several standpoints. First, at least a subset of MoRFs gain structure, 
indicating that there is an accessible free energy minimum upon interaction. Also, each of the 
PAT subfamilies have CCRs with distinct sequence (and presumably structural) signatures, and 
therefore each subfamily could potentially be specifically targeted. Several PATs have extended 
tails with a number of non-conserved MoRFs other than the CCR, and if these are functionally 
relevant, they may represent PAT-specific targets. Finally, searching the proteome for the specific 
patterns found in conserved MoRFs (for instance, Nx[Y/F]xxGxxxxN in Ras PATs) yields little 
results, with the only hits having proline breakers within the helical-prone region. Therefore, the 
sequence and structure of the MoRF is likely biologically unique.   
There are few examples of targeting intrinsic disorder with small molecules in the 
literature, potentially because of the relative novelty of the field and its concepts. Small molecules 
were able to induce misfolding of c-Myc, and this alternate conformation was not able to bind its 
cognate partner Max (280-282). Structured partners of disordered proteins have also been targets 
for small molecule inhibition. For example, p53 is an intrinsically disordered protein that is required 
to gain structure in order to bind to MDM2, and small molecules have been designed that bind to 
MDM2 and disrupt this interaction (283-285).  
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6.3 Further Applications of IDPs to the Field of Palmitoylation 
 Throughout this dissertation, I have mentioned that solving the structure of a zDHHC PAT 
is critical for advancing the field of palmitoylation. However, each of my three studies presented 
in this dissertation have demonstrated that understanding intrinsic disorder in palmitoylation 
enzymes and substrates is also critical to our understanding of this process. First, intrinsic 
disorder appears to be one of the determinants of substrate palmitoylation propensity. In several 
other enzyme-substrate systems, disorder surrounding a substrate residue is required to fit an 
enzyme active site, and palmitoylation may have a similar mechanism. Next, a conserved region 
of disorder-to-order transition may potentially regulate PAT activity via a protein-protein 
interaction, and this region is required to be intrinsically disordered in order to be able to 
dynamically modulate interaction levels. Finally, a proline-rich, non-conserved region likely to be 
disordered in the zDHHC9 C-terminus regulates protein localization, and while the molecular 
mechanisms are unclear, disorder likely plays a critical part in this process.  
 Besides further exploration of these particular topics, my exploration of the field of 
palmitoylation using the conceptual framework of intrinsic disorder has hinted at several other 
potentially interesting regions in zDHHC PATs. I have previously explored Ynl155W, which at the 
time was uncharacterized. This protein has no transmembrane domains and an AN1-type zinc 
finger, which is highly homologous to the DHHC-CRD; therefore, we were interested in this protein 
as a potential cytosolic palmitoyltransferase. While we never found any evidence of activity and 
this protein was subsequently characterized to have ubiquitin-binding functions (286), NMR 
structures of AN1-type zinc fingers show little secondary structure, with protein rigidity coordinated 
by zinc. Therefore, the homologous DHHC-CRD may have similar characteristics, where the 
rigidity of the active site residues is stabilized by zinc and not secondary structure.  
 The ER lumen facing loops of zDHHC PATs may also prove to be interesting to study. 
They often vary in size and sometimes have regions predicted to undergo changes in structure. 
While no studies have uncovered functional relevance of these loops, very little attention has been 
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paid to these regions. One intriguing example is in zDHHC16, which is predicted to have a large 
loop between TM2 and TM3. This loop has 21% identity (29% similarity) to a 75aa long ATP-
binding region in M-creatine kinase (270), and therefore this region may be a binding site for a 
yet to be identified molecule. Regardless of the mechanism, uncovering functional relevance of 
these loops would have significant implications in terms of regulation and signaling cascades of 
PATs, as extracellular and lumenal regulation of PATs is underexplored in the field. 
 On a similar note, the region between TM2 and the DHHC-CRD may be another area of 
interest. Like the extracellular/lumenal loops, this region is usually predicted to be disordered, 
often varies in size, and sometimes has dips in disorder plots reminiscent of MoRF-like regions. 
An interesting case is human zDHHC7, which has two isoforms. The second isoform has a 37aa 
insertion directly after TM2, and this addition displays a dip in the disorder plot suggesting some 
level of disorder-to-order propensity. If this region undergoes structural changes upon interaction 
with membranes or proteins, or serves as a recognition site for modification (it is predicted to be 
phosphorylated), this region could conceivably regulate some aspect of PAT function.  
 Finally, as I have mentioned previously, several PATs such as zDHHC8 and zDHHC14 
have long termini with multiple predicted MoRFs (161). These MoRFs do not have sequence 
similarity to the conserved MoRF described in Chapter 4, or to MoRFs in other PATs, and 
therefore are likely not conserved modes of regulation. Nevertheless, there is potentially 
interesting biological regulation to be found in these regions. For instance, a splice variant of 
zDHHC14 almost perfectly excises one of these non-conserved MoRFs. While this may be purely 
coincidental, correlations between alternative splicing and intrinsic disorder have been well-noted 
in the literature (139). Targeted splicing of these non-conserved MoRFs may be a method of 
modifying regulatory mechanisms such as stability or substrate recognition, while not interfering 
with catalysis. 
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6.4 Final Remarks  
 In closing, application of the conceptual framework of intrinsic disorder to the burgeoning 
field of palmitoylation has been a challenging, yet rewarding endeavor. Traditionally, principles of 
intrinsic disorder have been primarily applied to relatively well-studied fields such as amyloid 
proteins, chaperones, oncoproteins, and tumor suppressors. While results yielded through this 
type of research have been invaluable to our understanding of biology, studies of intrinsic disorder 
in more nascent fields, even outside of palmitoylation, have yielded unexpected insights. Some 
of the interesting biology that has been uncovered by such studies include IDPR regulating the 
formation of ‘membrane-less’ organelles, IDPR threading through transmembrane pore proteins, 
and IDPR driving of membrane curvature. Continued application of the conceptual framework of 
intrinsically disordered proteins to emerging fields will more than likely result in their accelerated 
development. 
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